Search Results For:
- Search results for:
- covid 19
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Multilateral organization
Diagnostic
Commercialization
- Equitable Access | Affordable pricing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Liability | Representations & Warranties
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MSD - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Liability | Representations & Warranties
- Term & termination | Term of agreement
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Liability | Indemnification & liability
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[qs] => covid 19
)
[filters] => Array
(
[text_search] => covid 19
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[post__in] => Array
(
[0] => 4808
[1] => 4807
[2] => 4806
[3] => 4805
[4] => 4804
[5] => 4802
[6] => 4801
[7] => 4800
[8] => 4798
[9] => 4797
[10] => 4796
[11] => 4661
[12] => 4147
[13] => 4601
[14] => 4148
[15] => 4223
[16] => 4222
[17] => 4221
[18] => 4220
[19] => 4219
[20] => 4218
[21] => 4217
[22] => 4216
[23] => 4215
[24] => 4214
[25] => 4213
[26] => 4212
[27] => 4210
[28] => 4209
[29] => 4205
[30] => 4204
[31] => 4201
[32] => 4200
[33] => 4161
[34] => 4159
[35] => 4158
[36] => 4157
[37] => 4156
[38] => 4155
[39] => 4154
[40] => 4153
[41] => 4152
[42] => 4151
[43] => 4150
[44] => 4149
[45] => 4146
[46] => 4141
[47] => 4140
[48] => 4139
[49] => 4138
[50] => 4137
[51] => 4136
[52] => 4135
[53] => 4134
[54] => 4133
[55] => 4131
[56] => 4130
[57] => 4129
[58] => 4128
[59] => 4058
[60] => 4054
[61] => 4051
[62] => 4050
[63] => 4047
[64] => 4046
[65] => 4045
[66] => 4043
[67] => 4042
[68] => 4041
[69] => 4040
[70] => 4038
[71] => 4036
[72] => 4035
[73] => 4032
[74] => 4029
[75] => 4028
[76] => 4024
[77] => 4022
[78] => 4021
[79] => 4020
[80] => 4017
[81] => 4016
[82] => 4014
[83] => 4013
[84] => 4012
[85] => 4011
[86] => 4009
[87] => 4007
[88] => 4006
[89] => 4004
[90] => 4003
[91] => 4002
[92] => 4001
[93] => 3997
[94] => 3869
[95] => 3886
[96] => 3884
[97] => 3883
[98] => 3882
[99] => 3881
[100] => 3880
[101] => 3878
[102] => 3877
[103] => 3876
[104] => 3875
[105] => 3874
[106] => 3873
[107] => 3870
[108] => 3863
[109] => 3861
[110] => 3860
[111] => 3859
[112] => 3858
[113] => 3857
[114] => 3856
[115] => 3855
[116] => 3854
[117] => 3852
[118] => 3851
[119] => 3849
[120] => 3848
[121] => 3847
[122] => 3846
[123] => 3845
[124] => 3819
[125] => 3812
[126] => 3810
[127] => 3809
[128] => 3808
[129] => 3807
[130] => 3806
[131] => 3805
[132] => 3804
[133] => 3803
[134] => 3802
[135] => 3801
[136] => 3800
[137] => 3799
[138] => 3798
[139] => 3797
[140] => 3796
[141] => 3792
[142] => 3791
[143] => 3789
[144] => 3788
[145] => 3786
[146] => 3785
[147] => 3784
[148] => 3783
[149] => 3782
[150] => 3781
[151] => 3778
[152] => 3769
[153] => 3768
[154] => 3765
[155] => 3764
[156] => 3758
[157] => 3741
[158] => 3696
[159] => 3495
[160] => 3493
[161] => 3436
[162] => 3434
[163] => 3433
[164] => 3431
[165] => 3430
[166] => 3428
[167] => 3427
[168] => 3426
[169] => 3424
[170] => 3422
[171] => 3421
[172] => 3420
[173] => 3372
[174] => 3370
[175] => 3368
[176] => 3366
[177] => 3364
[178] => 3361
[179] => 3360
[180] => 3356
[181] => 3354
[182] => 3352
[183] => 3221
[184] => 3220
[185] => 3219
[186] => 3218
[187] => 3217
[188] => 3216
[189] => 3215
[190] => 3127
[191] => 3126
[192] => 3125
[193] => 3124
[194] => 3123
[195] => 3122
[196] => 3121
[197] => 3120
[198] => 3119
[199] => 2956
[200] => 2961
[201] => 2965
[202] => 2947
[203] => 2960
[204] => 2964
[205] => 2958
[206] => 2949
[207] => 2957
[208] => 2962
[209] => 2945
[210] => 2909
[211] => 2908
[212] => 2907
[213] => 2893
[214] => 2892
[215] => 2890
[216] => 2889
[217] => 2885
[218] => 2824
[219] => 2823
[220] => 2822
[221] => 2820
[222] => 2744
[223] => 2749
[224] => 2748
[225] => 2743
[226] => 2742
[227] => 2741
[228] => 2739
[229] => 2737
[230] => 2736
[231] => 2734
[232] => 2543
[233] => 2540
[234] => 2541
[235] => 2542
[236] => 2544
[237] => 2545
[238] => 2547
[239] => 2549
[240] => 2553
[241] => 2457
[242] => 2461
[243] => 2462
[244] => 2463
[245] => 2464
[246] => 2465
[247] => 2466
[248] => 2467
[249] => 2470
[250] => 2473
[251] => 2474
[252] => 2475
[253] => 2476
[254] => 2477
[255] => 2479
[256] => 2481
[257] => 2482
[258] => 2471
[259] => 2454
[260] => 2452
[261] => 2450
[262] => 2449
[263] => 2448
[264] => 2444
[265] => 2443
[266] => 2442
[267] => 2441
[268] => 2426
[269] => 2424
[270] => 4808
[271] => 4807
[272] => 4806
[273] => 4805
[274] => 4804
[275] => 4802
[276] => 4801
[277] => 4800
[278] => 4798
[279] => 4797
[280] => 4796
[281] => 4661
[282] => 4147
[283] => 4601
[284] => 4148
[285] => 4223
[286] => 4222
[287] => 4221
[288] => 4220
[289] => 4219
[290] => 4218
[291] => 4217
[292] => 4216
[293] => 4215
[294] => 4214
[295] => 4213
[296] => 4212
[297] => 4210
[298] => 4209
[299] => 4205
[300] => 4204
[301] => 4201
[302] => 4200
[303] => 4161
[304] => 4159
[305] => 4158
[306] => 4157
[307] => 4156
[308] => 4155
[309] => 4154
[310] => 4153
[311] => 4152
[312] => 4151
[313] => 4150
[314] => 4149
[315] => 4146
[316] => 4141
[317] => 4140
[318] => 4139
[319] => 4138
[320] => 4137
[321] => 4136
[322] => 4135
[323] => 4134
[324] => 4133
[325] => 4131
[326] => 4130
[327] => 4129
[328] => 4128
[329] => 4058
[330] => 4054
[331] => 4051
[332] => 4050
[333] => 4047
[334] => 4046
[335] => 4045
[336] => 4043
[337] => 4042
[338] => 4041
[339] => 4040
[340] => 4038
[341] => 4036
[342] => 4035
[343] => 4032
[344] => 4029
[345] => 4028
[346] => 4024
[347] => 4022
[348] => 4021
[349] => 4020
[350] => 4017
[351] => 4016
[352] => 4014
[353] => 4013
[354] => 4012
[355] => 4011
[356] => 4009
[357] => 4007
[358] => 4006
[359] => 4004
[360] => 4003
[361] => 4002
[362] => 4001
[363] => 3997
[364] => 3869
[365] => 3886
[366] => 3884
[367] => 3883
[368] => 3882
[369] => 3881
[370] => 3880
[371] => 3878
[372] => 3877
[373] => 3876
[374] => 3875
[375] => 3874
[376] => 3873
[377] => 3870
[378] => 3863
[379] => 3861
[380] => 3860
[381] => 3859
[382] => 3858
[383] => 3857
[384] => 3856
[385] => 3855
[386] => 3854
[387] => 3852
[388] => 3851
[389] => 3849
[390] => 3848
[391] => 3847
[392] => 3846
[393] => 3845
[394] => 3819
[395] => 3812
[396] => 3810
[397] => 3809
[398] => 3808
[399] => 3807
[400] => 3806
[401] => 3805
[402] => 3804
[403] => 3803
[404] => 3802
[405] => 3801
[406] => 3800
[407] => 3799
[408] => 3798
[409] => 3797
[410] => 3796
[411] => 3792
[412] => 3791
[413] => 3789
[414] => 3788
[415] => 3786
[416] => 3785
[417] => 3784
[418] => 3783
[419] => 3782
[420] => 3781
[421] => 3778
[422] => 3769
[423] => 3768
[424] => 3765
[425] => 3764
[426] => 3758
[427] => 3741
[428] => 3696
[429] => 3495
[430] => 3493
[431] => 3436
[432] => 3434
[433] => 3433
[434] => 3431
[435] => 3430
[436] => 3428
[437] => 3427
[438] => 3426
[439] => 3424
[440] => 3422
[441] => 3421
[442] => 3420
[443] => 3372
[444] => 3370
[445] => 3368
[446] => 3366
[447] => 3364
[448] => 3361
[449] => 3360
[450] => 3356
[451] => 3354
[452] => 3352
[453] => 3221
[454] => 3220
[455] => 3219
[456] => 3218
[457] => 3217
[458] => 3216
[459] => 3215
[460] => 3127
[461] => 3126
[462] => 3125
[463] => 3124
[464] => 3123
[465] => 3122
[466] => 3121
[467] => 3120
[468] => 3119
[469] => 2956
[470] => 2961
[471] => 2965
[472] => 2947
[473] => 2960
[474] => 2964
[475] => 2958
[476] => 2949
[477] => 2957
[478] => 2962
[479] => 2945
[480] => 2909
[481] => 2908
[482] => 2907
[483] => 2893
[484] => 2892
[485] => 2890
[486] => 2889
[487] => 2885
[488] => 2824
[489] => 2823
[490] => 2822
[491] => 2820
[492] => 2744
[493] => 2749
[494] => 2748
[495] => 2743
[496] => 2742
[497] => 2741
[498] => 2739
[499] => 2737
[500] => 2736
[501] => 2734
[502] => 2543
[503] => 2540
[504] => 2541
[505] => 2542
[506] => 2544
[507] => 2545
[508] => 2547
[509] => 2549
[510] => 2553
[511] => 2457
[512] => 2461
[513] => 2462
[514] => 2463
[515] => 2464
[516] => 2465
[517] => 2466
[518] => 2467
[519] => 2470
[520] => 2473
[521] => 2474
[522] => 2475
[523] => 2476
[524] => 2477
[525] => 2479
[526] => 2481
[527] => 2482
[528] => 2471
[529] => 2454
[530] => 2452
[531] => 2450
[532] => 2449
[533] => 2448
[534] => 2444
[535] => 2443
[536] => 2442
[537] => 2441
[538] => 2426
[539] => 2424
[540] => 3909
[541] => 3908
[542] => 3906
[543] => 3904
[544] => 3903
[545] => 3901
[546] => 3900
[547] => 3899
[548] => 3898
[549] => 3897
[550] => 3896
[551] => 3895
[552] => 3892
[553] => 3891
[554] => 3890
[555] => 3418
[556] => 3417
[557] => 3416
[558] => 3415
[559] => 3414
[560] => 3413
[561] => 3412
[562] => 3411
[563] => 3410
[564] => 3409
[565] => 3406
[566] => 3304
[567] => 2873
[568] => 2872
[569] => 2870
[570] => 2869
[571] => 2867
)
)
[text_agreement_args] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
)
[text_provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
)
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] =>
[text_agreement_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
)
[query_vars] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[orderby] => title
[order] => ASC
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 2
[search_terms] => Array
(
[0] => covid
[1] => 19
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}'
[1] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}'
)
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT DISTINCT wpry_posts.*
FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) )
WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) ) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
ORDER BY wpry_posts.post_title ASC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 2438
[post_author] => 5
[post_date] => 2021-01-19 06:43:39
[post_date_gmt] => 2021-01-19 06:43:39
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:05:25
[post_modified_gmt] => 2021-09-15 12:05:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2438
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4207
[post_author] => 5
[post_date] => 2022-03-02 11:38:41
[post_date_gmt] => 2022-03-02 11:38:41
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-02 11:38:51
[post_modified_gmt] => 2022-03-02 11:38:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4207
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4126
[post_author] => 5
[post_date] => 2022-01-28 13:33:11
[post_date_gmt] => 2022-01-28 13:33:11
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:33:11
[post_modified_gmt] => 2022-01-28 13:33:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4126
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2882
[post_author] => 6
[post_date] => 2021-05-14 14:03:29
[post_date_gmt] => 2021-05-14 14:03:29
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 11:58:31
[post_modified_gmt] => 2021-09-15 11:58:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2882
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4794
[post_author] => 5
[post_date] => 2022-05-23 13:54:39
[post_date_gmt] => 2022-05-23 13:54:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 13:54:39
[post_modified_gmt] => 2022-05-23 13:54:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4794
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 3817
[post_author] => 6
[post_date] => 2021-09-15 10:46:18
[post_date_gmt] => 2021-09-15 10:46:18
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 13:58:20
[post_modified_gmt] => 2021-12-13 13:58:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3817
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 3117
[post_author] => 6
[post_date] => 2021-06-03 14:15:12
[post_date_gmt] => 2021-06-03 14:15:12
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:00:38
[post_modified_gmt] => 2021-09-15 12:00:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3117
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 2538
[post_author] => 5
[post_date] => 2021-03-12 13:41:11
[post_date_gmt] => 2021-03-12 13:41:11
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => advance-purchase-agreement-for-the-production-purchase-and-supply-of-a-covid-19-vaccine-in-the-european-union-with-astrazeneca
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:05:41
[post_modified_gmt] => 2021-09-15 12:05:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2538
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 2468
[post_author] => 5
[post_date] => 2021-02-25 15:15:43
[post_date_gmt] => 2021-02-25 15:15:43
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => advance-purchase-agreement-for-the-development-production-advance-purchase-and-supply-of-a-covid-19-vaccine-for-eu-member-states-with-curevac
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:00:56
[post_modified_gmt] => 2021-09-15 12:00:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2468
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 3419
[post_author] => 6
[post_date] => 2021-07-01 01:45:34
[post_date_gmt] => 2021-07-01 01:45:34
[post_content] =>
[post_title] => Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-10 18:22:02
[post_modified_gmt] => 2021-11-10 18:22:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3419
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 3843
[post_author] => 5
[post_date] => 2021-11-05 10:54:08
[post_date_gmt] => 2021-11-05 10:54:08
[post_content] =>
[post_title] => Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-05 10:54:08
[post_modified_gmt] => 2021-11-05 10:54:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3843
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4142
[post_author] => 5
[post_date] => 2022-02-01 18:56:28
[post_date_gmt] => 2022-02-01 18:56:28
[post_content] =>
[post_title] => Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 07:30:00
[post_modified_gmt] => 2022-02-02 07:30:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4142
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 3867
[post_author] => 5
[post_date] => 2021-11-18 12:26:40
[post_date_gmt] => 2021-11-18 12:26:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 12:26:40
[post_modified_gmt] => 2021-11-18 12:26:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3867
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 3348
[post_author] => 5
[post_date] => 2021-06-30 13:13:40
[post_date_gmt] => 2021-06-30 13:13:40
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:18:24
[post_modified_gmt] => 2021-09-15 12:18:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3348
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 3794
[post_author] => 5
[post_date] => 2021-09-10 08:02:49
[post_date_gmt] => 2021-09-10 08:02:49
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:20:53
[post_modified_gmt] => 2021-09-15 12:20:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3794
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 4026
[post_author] => 5
[post_date] => 2021-12-21 11:36:17
[post_date_gmt] => 2021-12-21 11:36:17
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-21 11:36:17
[post_modified_gmt] => 2021-12-21 11:36:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4026
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 3213
[post_author] => 6
[post_date] => 2021-06-28 12:04:36
[post_date_gmt] => 2021-06-28 12:04:36
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:03:12
[post_modified_gmt] => 2021-09-15 12:03:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3213
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 2420
[post_author] => 5
[post_date] => 2020-12-14 14:59:07
[post_date_gmt] => 2020-12-14 14:59:07
[post_content] =>
[post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:03:29
[post_modified_gmt] => 2021-09-15 12:03:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2420
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 2943
[post_author] => 6
[post_date] => 2021-05-28 13:48:32
[post_date_gmt] => 2021-05-28 13:48:32
[post_content] =>
[post_title] => UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:12:31
[post_modified_gmt] => 2021-09-15 12:12:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2943
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 2817
[post_author] => 5
[post_date] => 2021-04-16 11:58:45
[post_date_gmt] => 2021-04-16 11:58:45
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-12 15:16:34
[post_modified_gmt] => 2022-01-12 15:16:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2817
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 3776
[post_author] => 5
[post_date] => 2021-09-09 11:24:04
[post_date_gmt] => 2021-09-09 11:24:04
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:12:55
[post_modified_gmt] => 2021-09-15 12:12:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3776
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 2446
[post_author] => 5
[post_date] => 2021-01-19 09:42:42
[post_date_gmt] => 2021-01-19 09:42:42
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => award-contract-no-w911qy20c0100-by-and-between-modernatx-inc-and-the-department-of-defense
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:03:43
[post_modified_gmt] => 2021-09-15 12:03:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2446
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 2732
[post_author] => 5
[post_date] => 2021-03-23 15:54:07
[post_date_gmt] => 2021-03-23 15:54:07
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:18:39
[post_modified_gmt] => 2021-09-15 12:18:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2732
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 2455
[post_author] => 5
[post_date] => 2021-02-25 15:19:51
[post_date_gmt] => 2021-02-25 15:19:51
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:13:19
[post_modified_gmt] => 2021-09-15 12:13:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2455
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 24
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 2438
[post_author] => 5
[post_date] => 2021-01-19 06:43:39
[post_date_gmt] => 2021-01-19 06:43:39
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:05:25
[post_modified_gmt] => 2021-09-15 12:05:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2438
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 24
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 1fc2d19f378284cf7496bf5ba612c2e6
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 2
[search_terms] => Array
(
[0] => covid
[1] => 19
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}'
[1] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}'
)
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT DISTINCT wpry_posts.*
FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) )
WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) ) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid 19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 1 WHEN wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' AND wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 2 WHEN wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' OR wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 3 WHEN wpry_posts.post_excerpt LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid 19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 4 WHEN wpry_posts.post_content LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid 19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 5 ELSE 6 END), wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:09:54
[post_modified_gmt] => 2022-05-24 09:09:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4807
[post_author] => 5
[post_date] => 2022-05-24 09:02:55
[post_date_gmt] => 2022-05-24 09:02:55
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:02:55
[post_modified_gmt] => 2022-05-24 09:02:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4806
[post_author] => 5
[post_date] => 2022-05-24 08:59:08
[post_date_gmt] => 2022-05-24 08:59:08
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:08
[post_modified_gmt] => 2022-05-24 08:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4805
[post_author] => 5
[post_date] => 2022-05-24 08:53:12
[post_date_gmt] => 2022-05-24 08:53:12
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:42
[post_modified_gmt] => 2022-05-24 08:59:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4804
[post_author] => 5
[post_date] => 2022-05-24 08:40:15
[post_date_gmt] => 2022-05-24 08:40:15
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:53:51
[post_modified_gmt] => 2022-05-24 08:53:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4802
[post_author] => 5
[post_date] => 2022-05-24 08:24:23
[post_date_gmt] => 2022-05-24 08:24:23
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:24:23
[post_modified_gmt] => 2022-05-24 08:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4801
[post_author] => 5
[post_date] => 2022-05-24 08:19:21
[post_date_gmt] => 2022-05-24 08:19:21
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:19:21
[post_modified_gmt] => 2022-05-24 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4800
[post_author] => 5
[post_date] => 2022-05-24 08:07:39
[post_date_gmt] => 2022-05-24 08:07:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:08:30
[post_modified_gmt] => 2022-05-24 08:08:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4797
[post_author] => 5
[post_date] => 2022-05-23 13:54:57
[post_date_gmt] => 2022-05-23 13:54:57
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 13:54:57
[post_modified_gmt] => 2022-05-23 13:54:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4796
[post_author] => 5
[post_date] => 2022-05-23 13:54:05
[post_date_gmt] => 2022-05-23 13:54:05
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:21:34
[post_modified_gmt] => 2022-05-23 14:21:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4661
[post_author] => 5
[post_date] => 2022-04-20 08:13:06
[post_date_gmt] => 2022-04-20 08:13:06
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:13:06
[post_modified_gmt] => 2022-04-20 08:13:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4661
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:22:54
[post_modified_gmt] => 2022-04-18 13:22:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 4601
[post_author] => 5
[post_date] => 2022-04-18 10:40:48
[post_date_gmt] => 2022-04-18 10:40:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:44:46
[post_modified_gmt] => 2022-04-18 10:44:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4601
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:55:19
[post_modified_gmt] => 2022-04-18 13:55:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 4223
[post_author] => 5
[post_date] => 2022-03-04 09:43:58
[post_date_gmt] => 2022-03-04 09:43:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 09:43:58
[post_modified_gmt] => 2022-03-04 09:43:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 4222
[post_author] => 5
[post_date] => 2022-03-04 09:14:41
[post_date_gmt] => 2022-03-04 09:14:41
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:51:38
[post_modified_gmt] => 2022-03-08 13:51:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 4221
[post_author] => 5
[post_date] => 2022-03-04 09:05:29
[post_date_gmt] => 2022-03-04 09:05:29
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 09:05:29
[post_modified_gmt] => 2022-03-04 09:05:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 4220
[post_author] => 5
[post_date] => 2022-03-04 08:47:04
[post_date_gmt] => 2022-03-04 08:47:04
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 08:47:04
[post_modified_gmt] => 2022-03-04 08:47:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 4219
[post_author] => 5
[post_date] => 2022-03-04 08:02:15
[post_date_gmt] => 2022-03-04 08:02:15
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 08:47:42
[post_modified_gmt] => 2022-03-04 08:47:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 4218
[post_author] => 5
[post_date] => 2022-03-03 14:17:53
[post_date_gmt] => 2022-03-03 14:17:53
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 14:17:53
[post_modified_gmt] => 2022-03-03 14:17:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 4217
[post_author] => 5
[post_date] => 2022-03-03 13:59:58
[post_date_gmt] => 2022-03-03 13:59:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 14:11:50
[post_modified_gmt] => 2022-03-03 14:11:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 4216
[post_author] => 5
[post_date] => 2022-03-03 13:45:21
[post_date_gmt] => 2022-03-03 13:45:21
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 13:45:46
[post_modified_gmt] => 2022-03-03 13:45:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 4215
[post_author] => 5
[post_date] => 2022-03-03 13:31:56
[post_date_gmt] => 2022-03-03 13:31:56
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 13:42:58
[post_modified_gmt] => 2022-03-03 13:42:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:17:07
[post_modified_gmt] => 2022-03-21 13:17:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 10:58:00
[post_modified_gmt] => 2022-03-03 10:58:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 4212
[post_author] => 5
[post_date] => 2022-03-02 14:54:16
[post_date_gmt] => 2022-03-02 14:54:16
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:51:03
[post_modified_gmt] => 2022-03-08 13:51:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4212
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 4210
[post_author] => 5
[post_date] => 2022-03-02 13:14:31
[post_date_gmt] => 2022-03-02 13:14:31
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-02 13:14:31
[post_modified_gmt] => 2022-03-02 13:14:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 4209
[post_author] => 5
[post_date] => 2022-03-02 12:07:13
[post_date_gmt] => 2022-03-02 12:07:13
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 10:05:30
[post_modified_gmt] => 2022-03-04 10:05:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4209
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 4205
[post_author] => 5
[post_date] => 2022-02-28 15:24:19
[post_date_gmt] => 2022-02-28 15:24:19
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 15:24:19
[post_modified_gmt] => 2022-02-28 15:24:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 4204
[post_author] => 5
[post_date] => 2022-02-28 14:53:11
[post_date_gmt] => 2022-02-28 14:53:11
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:53:11
[post_modified_gmt] => 2022-02-28 14:53:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 4201
[post_author] => 5
[post_date] => 2022-02-28 13:33:22
[post_date_gmt] => 2022-02-28 13:33:22
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:46:09
[post_modified_gmt] => 2022-02-28 14:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 4200
[post_author] => 5
[post_date] => 2022-02-28 13:13:29
[post_date_gmt] => 2022-02-28 13:13:29
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:54:57
[post_modified_gmt] => 2022-03-08 13:54:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:17:00
[post_modified_gmt] => 2022-04-18 13:17:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 4159
[post_author] => 5
[post_date] => 2022-02-02 13:10:48
[post_date_gmt] => 2022-02-02 13:10:48
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:16:05
[post_modified_gmt] => 2022-04-18 13:16:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 4158
[post_author] => 5
[post_date] => 2022-02-02 13:00:08
[post_date_gmt] => 2022-02-02 13:00:08
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:15:30
[post_modified_gmt] => 2022-04-18 13:15:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 4157
[post_author] => 5
[post_date] => 2022-02-02 12:54:56
[post_date_gmt] => 2022-02-02 12:54:56
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:13:37
[post_modified_gmt] => 2022-04-18 13:13:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 4156
[post_author] => 5
[post_date] => 2022-02-02 12:36:42
[post_date_gmt] => 2022-02-02 12:36:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:51
[post_modified_gmt] => 2022-04-18 13:12:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 4155
[post_author] => 5
[post_date] => 2022-02-02 12:19:16
[post_date_gmt] => 2022-02-02 12:19:16
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:26
[post_modified_gmt] => 2022-04-18 13:12:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 4154
[post_author] => 5
[post_date] => 2022-02-02 12:13:41
[post_date_gmt] => 2022-02-02 12:13:41
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 12:13:41
[post_modified_gmt] => 2022-02-02 12:13:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4154
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 4153
[post_author] => 5
[post_date] => 2022-02-02 12:10:13
[post_date_gmt] => 2022-02-02 12:10:13
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:02:30
[post_modified_gmt] => 2022-04-18 13:02:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4153
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 4152
[post_author] => 5
[post_date] => 2022-02-02 11:51:54
[post_date_gmt] => 2022-02-02 11:51:54
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:02:06
[post_modified_gmt] => 2022-04-18 13:02:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 4151
[post_author] => 5
[post_date] => 2022-02-02 11:39:24
[post_date_gmt] => 2022-02-02 11:39:24
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:35
[post_modified_gmt] => 2022-04-18 13:01:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:03
[post_modified_gmt] => 2022-04-18 13:01:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:00:34
[post_modified_gmt] => 2022-04-18 13:00:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 4146
[post_author] => 5
[post_date] => 2022-02-02 07:28:42
[post_date_gmt] => 2022-02-02 07:28:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 12:57:05
[post_modified_gmt] => 2022-04-18 12:57:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4146
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 4141
[post_author] => 5
[post_date] => 2022-01-31 14:31:23
[post_date_gmt] => 2022-01-31 14:31:23
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:33:23
[post_modified_gmt] => 2022-01-31 14:33:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 4140
[post_author] => 5
[post_date] => 2022-01-31 14:22:03
[post_date_gmt] => 2022-01-31 14:22:03
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:11:05
[post_modified_gmt] => 2022-03-09 13:11:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 4139
[post_author] => 5
[post_date] => 2022-01-31 14:18:32
[post_date_gmt] => 2022-01-31 14:18:32
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 11:35:27
[post_modified_gmt] => 2022-02-11 11:35:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 4138
[post_author] => 5
[post_date] => 2022-01-31 14:09:33
[post_date_gmt] => 2022-01-31 14:09:33
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:09:33
[post_modified_gmt] => 2022-01-31 14:09:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4138
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 4137
[post_author] => 5
[post_date] => 2022-01-31 13:53:37
[post_date_gmt] => 2022-01-31 13:53:37
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:54:45
[post_modified_gmt] => 2022-01-31 13:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 4136
[post_author] => 5
[post_date] => 2022-01-31 13:42:47
[post_date_gmt] => 2022-01-31 13:42:47
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:42:47
[post_modified_gmt] => 2022-01-31 13:42:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 4135
[post_author] => 5
[post_date] => 2022-01-31 13:25:08
[post_date_gmt] => 2022-01-31 13:25:08
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:25:08
[post_modified_gmt] => 2022-01-31 13:25:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 4134
[post_author] => 5
[post_date] => 2022-01-31 12:56:28
[post_date_gmt] => 2022-01-31 12:56:28
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:56:28
[post_modified_gmt] => 2022-01-31 12:56:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:24:36
[post_modified_gmt] => 2022-01-31 12:24:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 16:31:13
[post_modified_gmt] => 2022-01-29 16:31:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 4130
[post_author] => 5
[post_date] => 2022-01-29 15:34:50
[post_date_gmt] => 2022-01-29 15:34:50
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 15:49:57
[post_modified_gmt] => 2022-01-29 15:49:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4129
[post_author] => 5
[post_date] => 2022-01-28 14:43:06
[post_date_gmt] => 2022-01-28 14:43:06
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 16:21:05
[post_modified_gmt] => 2022-03-31 16:21:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:45:11
[post_modified_gmt] => 2022-01-28 13:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4058
[post_author] => 5
[post_date] => 2022-01-04 14:25:52
[post_date_gmt] => 2022-01-04 14:25:52
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:25:52
[post_modified_gmt] => 2022-01-04 14:25:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4058
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 4054
[post_author] => 5
[post_date] => 2022-01-03 11:45:52
[post_date_gmt] => 2022-01-03 11:45:52
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 11:46:09
[post_modified_gmt] => 2022-01-03 11:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4054
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 4051
[post_author] => 5
[post_date] => 2022-01-03 11:01:41
[post_date_gmt] => 2022-01-03 11:01:41
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 10:37:08
[post_modified_gmt] => 2022-03-09 10:37:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 4050
[post_author] => 5
[post_date] => 2022-01-03 10:49:32
[post_date_gmt] => 2022-01-03 10:49:32
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:56:55
[post_modified_gmt] => 2022-01-03 10:56:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4050
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 4047
[post_author] => 5
[post_date] => 2021-12-27 17:17:36
[post_date_gmt] => 2021-12-27 17:17:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:43:10
[post_modified_gmt] => 2022-01-03 10:43:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4047
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 4046
[post_author] => 5
[post_date] => 2021-12-27 17:10:47
[post_date_gmt] => 2021-12-27 17:10:47
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:10:47
[post_modified_gmt] => 2021-12-27 17:10:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4046
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 4045
[post_author] => 5
[post_date] => 2021-12-27 17:07:25
[post_date_gmt] => 2021-12-27 17:07:25
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:07:25
[post_modified_gmt] => 2021-12-27 17:07:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4045
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 4043
[post_author] => 5
[post_date] => 2021-12-27 16:47:54
[post_date_gmt] => 2021-12-27 16:47:54
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:47:54
[post_modified_gmt] => 2021-12-27 16:47:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4043
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 4042
[post_author] => 5
[post_date] => 2021-12-27 16:41:56
[post_date_gmt] => 2021-12-27 16:41:56
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 10:56:31
[post_modified_gmt] => 2022-01-27 10:56:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4042
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 4041
[post_author] => 5
[post_date] => 2021-12-27 16:28:21
[post_date_gmt] => 2021-12-27 16:28:21
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:28:42
[post_modified_gmt] => 2021-12-27 16:28:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4041
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 4040
[post_author] => 5
[post_date] => 2021-12-27 15:24:04
[post_date_gmt] => 2021-12-27 15:24:04
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-14 12:58:21
[post_modified_gmt] => 2022-03-14 12:58:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 4038
[post_author] => 5
[post_date] => 2021-12-27 15:08:30
[post_date_gmt] => 2021-12-27 15:08:30
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:22:28
[post_modified_gmt] => 2022-01-24 12:22:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4038
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 4036
[post_author] => 5
[post_date] => 2021-12-26 17:01:45
[post_date_gmt] => 2021-12-26 17:01:45
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:22:53
[post_modified_gmt] => 2022-02-11 13:22:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4036
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 4035
[post_author] => 5
[post_date] => 2021-12-26 16:47:36
[post_date_gmt] => 2021-12-26 16:47:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-26 16:47:36
[post_modified_gmt] => 2021-12-26 16:47:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4035
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 4032
[post_author] => 5
[post_date] => 2021-12-26 16:32:27
[post_date_gmt] => 2021-12-26 16:32:27
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-22 14:37:29
[post_modified_gmt] => 2022-01-22 14:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4032
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 4029
[post_author] => 5
[post_date] => 2021-12-21 12:22:08
[post_date_gmt] => 2021-12-21 12:22:08
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:10:58
[post_modified_gmt] => 2022-01-24 12:10:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4029
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 4028
[post_author] => 5
[post_date] => 2021-12-21 11:55:28
[post_date_gmt] => 2021-12-21 11:55:28
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-21 11:56:51
[post_modified_gmt] => 2021-12-21 11:56:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4028
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 4024
[post_author] => 5
[post_date] => 2021-12-15 15:33:17
[post_date_gmt] => 2021-12-15 15:33:17
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 15:33:17
[post_modified_gmt] => 2021-12-15 15:33:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4024
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 4022
[post_author] => 5
[post_date] => 2021-12-15 14:49:36
[post_date_gmt] => 2021-12-15 14:49:36
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:51:23
[post_modified_gmt] => 2021-12-15 14:51:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4022
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 4021
[post_author] => 5
[post_date] => 2021-12-15 14:31:00
[post_date_gmt] => 2021-12-15 14:31:00
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:31:00
[post_modified_gmt] => 2021-12-15 14:31:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4021
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 4020
[post_author] => 5
[post_date] => 2021-12-15 14:24:47
[post_date_gmt] => 2021-12-15 14:24:47
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:24:47
[post_modified_gmt] => 2021-12-15 14:24:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4020
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 4017
[post_author] => 5
[post_date] => 2021-12-15 13:22:49
[post_date_gmt] => 2021-12-15 13:22:49
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 13:22:49
[post_modified_gmt] => 2021-12-15 13:22:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4017
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 4016
[post_author] => 5
[post_date] => 2021-12-15 13:20:07
[post_date_gmt] => 2021-12-15 13:20:07
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:34:02
[post_modified_gmt] => 2022-01-27 11:34:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4016
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 4014
[post_author] => 5
[post_date] => 2021-12-15 12:33:09
[post_date_gmt] => 2021-12-15 12:33:09
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:33:09
[post_modified_gmt] => 2021-12-15 12:33:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4014
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 4013
[post_author] => 5
[post_date] => 2021-12-15 12:16:20
[post_date_gmt] => 2021-12-15 12:16:20
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:17:01
[post_modified_gmt] => 2021-12-15 12:17:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4013
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 4012
[post_author] => 5
[post_date] => 2021-12-15 12:01:13
[post_date_gmt] => 2021-12-15 12:01:13
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:01:13
[post_modified_gmt] => 2021-12-15 12:01:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4012
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 4011
[post_author] => 5
[post_date] => 2021-12-14 15:21:54
[post_date_gmt] => 2021-12-14 15:21:54
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 11:48:20
[post_modified_gmt] => 2021-12-15 11:48:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4011
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 4009
[post_author] => 5
[post_date] => 2021-12-14 15:10:51
[post_date_gmt] => 2021-12-14 15:10:51
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:00:07
[post_modified_gmt] => 2022-03-09 11:00:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4009
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 4007
[post_author] => 5
[post_date] => 2021-12-14 08:51:32
[post_date_gmt] => 2021-12-14 08:51:32
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 08:51:44
[post_modified_gmt] => 2021-12-14 08:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4007
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 4006
[post_author] => 5
[post_date] => 2021-12-14 08:16:01
[post_date_gmt] => 2021-12-14 08:16:01
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 14:46:11
[post_modified_gmt] => 2022-03-23 14:46:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4006
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 4004
[post_author] => 5
[post_date] => 2021-12-14 07:57:41
[post_date_gmt] => 2021-12-14 07:57:41
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 07:57:41
[post_modified_gmt] => 2021-12-14 07:57:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4004
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 4003
[post_author] => 5
[post_date] => 2021-12-13 18:36:53
[post_date_gmt] => 2021-12-13 18:36:53
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:25:43
[post_modified_gmt] => 2022-02-11 13:25:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4003
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 4002
[post_author] => 5
[post_date] => 2021-12-13 18:28:05
[post_date_gmt] => 2021-12-13 18:28:05
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:41:28
[post_modified_gmt] => 2021-12-13 18:41:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4002
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 4001
[post_author] => 5
[post_date] => 2021-12-13 14:55:46
[post_date_gmt] => 2021-12-13 14:55:46
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:30:22
[post_modified_gmt] => 2021-12-13 18:30:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4001
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 3997
[post_author] => 5
[post_date] => 2021-12-13 14:24:49
[post_date_gmt] => 2021-12-13 14:24:49
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 14:24:59
[post_modified_gmt] => 2021-12-13 14:24:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3997
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 3869
[post_author] => 5
[post_date] => 2021-11-19 12:55:06
[post_date_gmt] => 2021-11-19 12:55:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-02 15:02:14
[post_modified_gmt] => 2021-12-02 15:02:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 3886
[post_author] => 5
[post_date] => 2021-11-18 16:36:37
[post_date_gmt] => 2021-11-18 16:36:37
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 06:09:26
[post_modified_gmt] => 2022-04-12 06:09:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3886
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 3884
[post_author] => 5
[post_date] => 2021-11-18 16:17:51
[post_date_gmt] => 2021-11-18 16:17:51
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:17:21
[post_modified_gmt] => 2022-03-09 11:17:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3884
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 3883
[post_author] => 5
[post_date] => 2021-11-18 16:10:24
[post_date_gmt] => 2021-11-18 16:10:24
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:48:26
[post_modified_gmt] => 2021-12-03 12:48:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3883
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 3882
[post_author] => 5
[post_date] => 2021-11-18 16:01:06
[post_date_gmt] => 2021-11-18 16:01:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:49:07
[post_modified_gmt] => 2021-12-03 12:49:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3882
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 3881
[post_author] => 5
[post_date] => 2021-11-18 15:52:45
[post_date_gmt] => 2021-11-18 15:52:45
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:52:45
[post_modified_gmt] => 2021-11-18 15:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3881
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 3880
[post_author] => 5
[post_date] => 2021-11-18 15:50:26
[post_date_gmt] => 2021-11-18 15:50:26
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:50:26
[post_modified_gmt] => 2021-11-18 15:50:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3880
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 3878
[post_author] => 5
[post_date] => 2021-11-18 15:08:19
[post_date_gmt] => 2021-11-18 15:08:19
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:08:19
[post_modified_gmt] => 2021-11-18 15:08:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3878
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 3877
[post_author] => 5
[post_date] => 2021-11-18 15:05:16
[post_date_gmt] => 2021-11-18 15:05:16
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:39:09
[post_modified_gmt] => 2022-01-27 11:39:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 3876
[post_author] => 5
[post_date] => 2021-11-18 14:51:40
[post_date_gmt] => 2021-11-18 14:51:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 14:51:40
[post_modified_gmt] => 2021-11-18 14:51:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3876
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 3875
[post_author] => 5
[post_date] => 2021-11-18 14:43:39
[post_date_gmt] => 2021-11-18 14:43:39
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 10:50:23
[post_modified_gmt] => 2021-11-22 10:50:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3875
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 3874
[post_author] => 5
[post_date] => 2021-11-18 14:29:06
[post_date_gmt] => 2021-11-18 14:29:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 08:08:10
[post_modified_gmt] => 2022-04-12 08:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3874
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 3873
[post_author] => 5
[post_date] => 2021-11-18 14:05:12
[post_date_gmt] => 2021-11-18 14:05:12
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:22:45
[post_modified_gmt] => 2021-11-19 12:22:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 3870
[post_author] => 5
[post_date] => 2021-11-18 12:58:35
[post_date_gmt] => 2021-11-18 12:58:35
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:25:29
[post_modified_gmt] => 2021-11-19 12:25:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 3863
[post_author] => 5
[post_date] => 2021-11-05 14:19:38
[post_date_gmt] => 2021-11-05 14:19:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:42
[post_modified_gmt] => 2022-04-18 09:22:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3863
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 3861
[post_author] => 5
[post_date] => 2021-11-05 13:59:54
[post_date_gmt] => 2021-11-05 13:59:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:26
[post_modified_gmt] => 2022-04-18 07:16:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3861
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 3860
[post_author] => 5
[post_date] => 2021-11-05 13:51:48
[post_date_gmt] => 2021-11-05 13:51:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:48
[post_modified_gmt] => 2022-04-18 07:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3860
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 3859
[post_author] => 5
[post_date] => 2021-11-05 13:44:47
[post_date_gmt] => 2021-11-05 13:44:47
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:28:57
[post_modified_gmt] => 2022-04-18 07:28:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3859
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 3858
[post_author] => 5
[post_date] => 2021-11-05 13:39:37
[post_date_gmt] => 2021-11-05 13:39:37
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:54:11
[post_modified_gmt] => 2022-04-18 07:54:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3858
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 3857
[post_author] => 5
[post_date] => 2021-11-05 13:37:12
[post_date_gmt] => 2021-11-05 13:37:12
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:41:41
[post_modified_gmt] => 2022-04-18 07:41:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3857
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 3856
[post_author] => 5
[post_date] => 2021-11-05 13:12:38
[post_date_gmt] => 2021-11-05 13:12:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:11:42
[post_modified_gmt] => 2022-04-18 08:11:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3856
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 3855
[post_author] => 5
[post_date] => 2021-11-05 13:10:25
[post_date_gmt] => 2021-11-05 13:10:25
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:05:19
[post_modified_gmt] => 2022-04-18 08:05:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3855
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 3854
[post_author] => 5
[post_date] => 2021-11-05 13:03:41
[post_date_gmt] => 2021-11-05 13:03:41
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:15:00
[post_modified_gmt] => 2022-04-18 08:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3854
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 3852
[post_author] => 5
[post_date] => 2021-11-05 12:43:57
[post_date_gmt] => 2021-11-05 12:43:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:33:20
[post_modified_gmt] => 2022-04-18 08:33:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3852
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 3851
[post_author] => 5
[post_date] => 2021-11-05 12:41:54
[post_date_gmt] => 2021-11-05 12:41:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:45:20
[post_modified_gmt] => 2022-04-18 08:45:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3851
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 3849
[post_author] => 5
[post_date] => 2021-11-05 12:30:09
[post_date_gmt] => 2021-11-05 12:30:09
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:52:12
[post_modified_gmt] => 2022-04-18 08:52:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3849
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 3848
[post_author] => 5
[post_date] => 2021-11-05 12:27:44
[post_date_gmt] => 2021-11-05 12:27:44
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:58:14
[post_modified_gmt] => 2022-04-18 08:58:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3848
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 3847
[post_author] => 5
[post_date] => 2021-11-05 12:25:40
[post_date_gmt] => 2021-11-05 12:25:40
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:07:16
[post_modified_gmt] => 2022-04-18 09:07:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3847
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 3846
[post_author] => 5
[post_date] => 2021-11-05 12:14:17
[post_date_gmt] => 2021-11-05 12:14:17
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:08:02
[post_modified_gmt] => 2022-04-18 09:08:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3846
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 3845
[post_author] => 5
[post_date] => 2021-11-05 11:56:34
[post_date_gmt] => 2021-11-05 11:56:34
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:20:20
[post_modified_gmt] => 2022-04-18 09:20:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3845
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 3819
[post_author] => 6
[post_date] => 2021-09-15 12:17:55
[post_date_gmt] => 2021-09-15 12:17:55
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 11:45:22
[post_modified_gmt] => 2021-12-15 11:45:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3819
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 3812
[post_author] => 5
[post_date] => 2021-09-10 12:44:57
[post_date_gmt] => 2021-09-10 12:44:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:13:50
[post_modified_gmt] => 2022-04-20 09:13:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3812
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 3810
[post_author] => 5
[post_date] => 2021-09-10 12:21:33
[post_date_gmt] => 2021-09-10 12:21:33
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:11:54
[post_modified_gmt] => 2022-04-20 07:11:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3810
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:19:45
[post_modified_gmt] => 2022-04-20 09:19:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:24:05
[post_modified_gmt] => 2022-04-20 07:24:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 3807
[post_author] => 5
[post_date] => 2021-09-10 11:55:25
[post_date_gmt] => 2021-09-10 11:55:25
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:42:12
[post_modified_gmt] => 2022-04-20 07:42:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 3806
[post_author] => 5
[post_date] => 2021-09-10 11:47:18
[post_date_gmt] => 2021-09-10 11:47:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:16:48
[post_modified_gmt] => 2022-04-20 09:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 3805
[post_author] => 5
[post_date] => 2021-09-10 11:33:53
[post_date_gmt] => 2021-09-10 11:33:53
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:46:59
[post_modified_gmt] => 2022-04-20 07:46:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 3804
[post_author] => 5
[post_date] => 2021-09-10 11:20:59
[post_date_gmt] => 2021-09-10 11:20:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:50:11
[post_modified_gmt] => 2022-04-20 07:50:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 3803
[post_author] => 5
[post_date] => 2021-09-10 10:54:42
[post_date_gmt] => 2021-09-10 10:54:42
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:51:06
[post_modified_gmt] => 2022-04-20 07:51:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3803
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 3802
[post_author] => 5
[post_date] => 2021-09-10 10:45:57
[post_date_gmt] => 2021-09-10 10:45:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:54:14
[post_modified_gmt] => 2022-04-20 07:54:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:05:17
[post_modified_gmt] => 2022-04-20 08:05:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 3800
[post_author] => 5
[post_date] => 2021-09-10 10:25:59
[post_date_gmt] => 2021-09-10 10:25:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:35:52
[post_modified_gmt] => 2022-04-20 08:35:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 3799
[post_author] => 5
[post_date] => 2021-09-10 10:07:18
[post_date_gmt] => 2021-09-10 10:07:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:44:40
[post_modified_gmt] => 2022-04-20 08:44:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3799
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 3798
[post_author] => 5
[post_date] => 2021-09-10 10:02:07
[post_date_gmt] => 2021-09-10 10:02:07
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:46:03
[post_modified_gmt] => 2022-04-20 08:46:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 3797
[post_author] => 5
[post_date] => 2021-09-10 09:54:44
[post_date_gmt] => 2021-09-10 09:54:44
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:53:13
[post_modified_gmt] => 2022-04-20 08:53:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 3796
[post_author] => 5
[post_date] => 2021-09-10 09:03:43
[post_date_gmt] => 2021-09-10 09:03:43
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:07:03
[post_modified_gmt] => 2022-04-20 09:07:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 3792
[post_author] => 5
[post_date] => 2021-09-09 14:23:13
[post_date_gmt] => 2021-09-09 14:23:13
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 12:44:33
[post_modified_gmt] => 2022-03-09 12:44:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3792
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 3791
[post_author] => 5
[post_date] => 2021-09-09 14:18:44
[post_date_gmt] => 2021-09-09 14:18:44
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:00:35
[post_modified_gmt] => 2021-11-04 09:00:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3791
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 3789
[post_author] => 5
[post_date] => 2021-09-09 14:07:30
[post_date_gmt] => 2021-09-09 14:07:30
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:42:42
[post_modified_gmt] => 2022-01-27 11:42:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3789
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 3788
[post_author] => 5
[post_date] => 2021-09-09 14:00:40
[post_date_gmt] => 2021-09-09 14:00:40
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:02:12
[post_modified_gmt] => 2021-11-04 09:02:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3788
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:55:09
[post_modified_gmt] => 2022-03-21 13:55:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 3785
[post_author] => 5
[post_date] => 2021-09-09 13:10:11
[post_date_gmt] => 2021-09-09 13:10:11
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:04:36
[post_modified_gmt] => 2021-11-04 09:04:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3785
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 3784
[post_author] => 5
[post_date] => 2021-09-09 13:03:52
[post_date_gmt] => 2021-09-09 13:03:52
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:12
[post_modified_gmt] => 2021-11-04 09:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3784
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 3783
[post_author] => 5
[post_date] => 2021-09-09 12:41:47
[post_date_gmt] => 2021-09-09 12:41:47
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:50
[post_modified_gmt] => 2021-11-04 09:05:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3783
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 3782
[post_author] => 5
[post_date] => 2021-09-09 12:36:36
[post_date_gmt] => 2021-09-09 12:36:36
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:50:50
[post_modified_gmt] => 2022-03-28 10:50:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 3781
[post_author] => 5
[post_date] => 2021-09-09 12:29:54
[post_date_gmt] => 2021-09-09 12:29:54
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:18:43
[post_modified_gmt] => 2021-11-23 14:18:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3781
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 3778
[post_author] => 5
[post_date] => 2021-09-09 11:52:53
[post_date_gmt] => 2021-09-09 11:52:53
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:35:12
[post_modified_gmt] => 2021-12-06 12:35:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3778
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[152] => WP_Post Object
(
[ID] => 3769
[post_author] => 5
[post_date] => 2021-09-02 14:55:06
[post_date_gmt] => 2021-09-02 14:55:06
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-novavax-covid-19-vaccine-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-02 15:00:21
[post_modified_gmt] => 2021-12-02 15:00:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3769
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[153] => WP_Post Object
(
[ID] => 3768
[post_author] => 5
[post_date] => 2021-09-02 14:27:00
[post_date_gmt] => 2021-09-02 14:27:00
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:19:56
[post_modified_gmt] => 2021-12-03 14:19:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3768
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[154] => WP_Post Object
(
[ID] => 3765
[post_author] => 5
[post_date] => 2021-09-01 14:09:03
[post_date_gmt] => 2021-09-01 14:09:03
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:49:00
[post_modified_gmt] => 2022-03-28 10:49:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[155] => WP_Post Object
(
[ID] => 3764
[post_author] => 5
[post_date] => 2021-09-01 12:17:32
[post_date_gmt] => 2021-09-01 12:17:32
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:15:32
[post_modified_gmt] => 2021-11-23 14:15:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3764
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[156] => WP_Post Object
(
[ID] => 3758
[post_author] => 5
[post_date] => 2021-08-26 12:04:03
[post_date_gmt] => 2021-08-26 12:04:03
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:43:14
[post_modified_gmt] => 2022-03-28 10:43:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[157] => WP_Post Object
(
[ID] => 3741
[post_author] => 5
[post_date] => 2021-08-24 09:13:39
[post_date_gmt] => 2021-08-24 09:13:39
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:32:22
[post_modified_gmt] => 2022-01-04 12:32:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[158] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:37:29
[post_modified_gmt] => 2022-01-18 12:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[159] => WP_Post Object
(
[ID] => 3495
[post_author] => 5
[post_date] => 2021-08-10 13:06:45
[post_date_gmt] => 2021-08-10 13:06:45
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dod-moderna-covid-19-vaccine-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:12:04
[post_modified_gmt] => 2021-11-29 14:12:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3495
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[160] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:24:35
[post_modified_gmt] => 2022-02-28 08:24:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[161] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:36
[post_modified_gmt] => 2022-04-18 09:22:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[162] => WP_Post Object
(
[ID] => 3434
[post_author] => 6
[post_date] => 2021-07-01 03:44:18
[post_date_gmt] => 2021-07-01 03:44:18
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:28:59
[post_modified_gmt] => 2022-04-18 09:28:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3434
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[163] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:32:11
[post_modified_gmt] => 2022-04-18 09:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[164] => WP_Post Object
(
[ID] => 3431
[post_author] => 6
[post_date] => 2021-07-01 03:38:49
[post_date_gmt] => 2021-07-01 03:38:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:41:10
[post_modified_gmt] => 2022-04-18 09:41:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3431
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[165] => WP_Post Object
(
[ID] => 3430
[post_author] => 6
[post_date] => 2021-07-01 03:27:51
[post_date_gmt] => 2021-07-01 03:27:51
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:45:31
[post_modified_gmt] => 2022-04-18 09:45:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3430
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[166] => WP_Post Object
(
[ID] => 3428
[post_author] => 6
[post_date] => 2021-07-01 03:24:00
[post_date_gmt] => 2021-07-01 03:24:00
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:47:22
[post_modified_gmt] => 2022-04-18 09:47:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3428
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[167] => WP_Post Object
(
[ID] => 3427
[post_author] => 6
[post_date] => 2021-07-01 03:22:23
[post_date_gmt] => 2021-07-01 03:22:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:49:38
[post_modified_gmt] => 2022-04-18 09:49:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[168] => WP_Post Object
(
[ID] => 3426
[post_author] => 6
[post_date] => 2021-07-01 03:06:23
[post_date_gmt] => 2021-07-01 03:06:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:28:05
[post_modified_gmt] => 2022-04-18 10:28:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[169] => WP_Post Object
(
[ID] => 3424
[post_author] => 6
[post_date] => 2021-07-01 03:03:57
[post_date_gmt] => 2021-07-01 03:03:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:47:10
[post_modified_gmt] => 2022-04-18 10:47:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[170] => WP_Post Object
(
[ID] => 3422
[post_author] => 6
[post_date] => 2021-07-01 02:58:21
[post_date_gmt] => 2021-07-01 02:58:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:48:25
[post_modified_gmt] => 2022-04-18 10:48:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[171] => WP_Post Object
(
[ID] => 3421
[post_author] => 6
[post_date] => 2021-07-01 02:56:30
[post_date_gmt] => 2021-07-01 02:56:30
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:51:44
[post_modified_gmt] => 2022-04-18 10:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3421
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[172] => WP_Post Object
(
[ID] => 3420
[post_author] => 6
[post_date] => 2021-07-01 02:52:05
[post_date_gmt] => 2021-07-01 02:52:05
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 11:01:10
[post_modified_gmt] => 2022-04-18 11:01:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3420
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[173] => WP_Post Object
(
[ID] => 3372
[post_author] => 5
[post_date] => 2021-06-30 15:06:19
[post_date_gmt] => 2021-06-30 15:06:19
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:05:39
[post_modified_gmt] => 2022-03-09 13:05:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3372
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[174] => WP_Post Object
(
[ID] => 3370
[post_author] => 5
[post_date] => 2021-06-30 15:01:06
[post_date_gmt] => 2021-06-30 15:01:06
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:51:17
[post_modified_gmt] => 2022-01-27 11:51:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3370
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[175] => WP_Post Object
(
[ID] => 3368
[post_author] => 5
[post_date] => 2021-06-30 14:58:39
[post_date_gmt] => 2021-06-30 14:58:39
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:10:31
[post_modified_gmt] => 2021-08-24 08:10:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3368
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[176] => WP_Post Object
(
[ID] => 3366
[post_author] => 5
[post_date] => 2021-06-30 14:53:53
[post_date_gmt] => 2021-06-30 14:53:53
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:53:53
[post_modified_gmt] => 2021-06-30 14:53:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3366
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[177] => WP_Post Object
(
[ID] => 3364
[post_author] => 5
[post_date] => 2021-06-30 14:47:34
[post_date_gmt] => 2021-06-30 14:47:34
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-02 12:46:22
[post_modified_gmt] => 2021-09-02 12:46:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3364
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[178] => WP_Post Object
(
[ID] => 3361
[post_author] => 5
[post_date] => 2021-06-30 14:30:51
[post_date_gmt] => 2021-06-30 14:30:51
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:22:31
[post_modified_gmt] => 2021-12-03 14:22:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3361
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[179] => WP_Post Object
(
[ID] => 3360
[post_author] => 5
[post_date] => 2021-06-30 14:28:40
[post_date_gmt] => 2021-06-30 14:28:40
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:53:01
[post_modified_gmt] => 2021-12-07 11:53:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3360
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[180] => WP_Post Object
(
[ID] => 3356
[post_author] => 5
[post_date] => 2021-06-30 13:53:23
[post_date_gmt] => 2021-06-30 13:53:23
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:44:11
[post_modified_gmt] => 2022-03-28 10:44:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[181] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[182] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-30 12:46:37
[post_modified_gmt] => 2022-03-30 12:46:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[183] => WP_Post Object
(
[ID] => 3221
[post_author] => 6
[post_date] => 2021-06-28 12:23:49
[post_date_gmt] => 2021-06-28 12:23:49
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:24
[post_modified_gmt] => 2021-08-23 09:51:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[184] => WP_Post Object
(
[ID] => 3220
[post_author] => 6
[post_date] => 2021-06-28 12:22:09
[post_date_gmt] => 2021-06-28 12:22:09
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:08:44
[post_modified_gmt] => 2022-03-09 13:08:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[185] => WP_Post Object
(
[ID] => 3219
[post_author] => 6
[post_date] => 2021-06-28 12:19:29
[post_date_gmt] => 2021-06-28 12:19:29
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:33
[post_modified_gmt] => 2021-08-23 09:51:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[186] => WP_Post Object
(
[ID] => 3218
[post_author] => 6
[post_date] => 2021-06-28 12:16:20
[post_date_gmt] => 2021-06-28 12:16:20
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:37
[post_modified_gmt] => 2021-08-23 09:51:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[187] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:41
[post_modified_gmt] => 2021-08-23 09:51:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[188] => WP_Post Object
(
[ID] => 3216
[post_author] => 6
[post_date] => 2021-06-28 12:11:22
[post_date_gmt] => 2021-06-28 12:11:22
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:45
[post_modified_gmt] => 2021-08-23 09:51:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[189] => WP_Post Object
(
[ID] => 3215
[post_author] => 6
[post_date] => 2021-06-28 12:07:55
[post_date_gmt] => 2021-06-28 12:07:55
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:48
[post_modified_gmt] => 2021-08-23 09:51:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[190] => WP_Post Object
(
[ID] => 3127
[post_author] => 6
[post_date] => 2021-06-03 15:08:41
[post_date_gmt] => 2021-06-03 15:08:41
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:45
[post_modified_gmt] => 2021-08-23 09:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[191] => WP_Post Object
(
[ID] => 3126
[post_author] => 6
[post_date] => 2021-06-03 15:05:40
[post_date_gmt] => 2021-06-03 15:05:40
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:49
[post_modified_gmt] => 2021-08-23 09:52:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[192] => WP_Post Object
(
[ID] => 3125
[post_author] => 6
[post_date] => 2021-06-03 15:03:17
[post_date_gmt] => 2021-06-03 15:03:17
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:13:17
[post_modified_gmt] => 2022-03-09 13:13:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[193] => WP_Post Object
(
[ID] => 3124
[post_author] => 6
[post_date] => 2021-06-03 15:01:23
[post_date_gmt] => 2021-06-03 15:01:23
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:56
[post_modified_gmt] => 2021-08-23 09:52:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[194] => WP_Post Object
(
[ID] => 3123
[post_author] => 6
[post_date] => 2021-06-03 14:51:22
[post_date_gmt] => 2021-06-03 14:51:22
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 13:12:13
[post_modified_gmt] => 2021-11-23 13:12:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[195] => WP_Post Object
(
[ID] => 3122
[post_author] => 6
[post_date] => 2021-06-03 14:45:44
[post_date_gmt] => 2021-06-03 14:45:44
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:08:08
[post_modified_gmt] => 2021-11-23 15:08:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[196] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:08
[post_modified_gmt] => 2021-08-23 09:53:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[197] => WP_Post Object
(
[ID] => 3120
[post_author] => 6
[post_date] => 2021-06-03 14:24:03
[post_date_gmt] => 2021-06-03 14:24:03
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:12
[post_modified_gmt] => 2021-08-23 09:53:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[198] => WP_Post Object
(
[ID] => 3119
[post_author] => 6
[post_date] => 2021-06-03 14:21:50
[post_date_gmt] => 2021-06-03 14:21:50
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:15
[post_modified_gmt] => 2021-08-23 09:53:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[199] => WP_Post Object
(
[ID] => 2956
[post_author] => 6
[post_date] => 2021-05-28 18:56:15
[post_date_gmt] => 2021-05-28 18:56:15
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:06
[post_modified_gmt] => 2021-08-23 10:02:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2956
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[200] => WP_Post Object
(
[ID] => 2961
[post_author] => 6
[post_date] => 2021-05-28 18:55:47
[post_date_gmt] => 2021-05-28 18:55:47
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:41:04
[post_modified_gmt] => 2021-11-23 12:41:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2961
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[201] => WP_Post Object
(
[ID] => 2965
[post_author] => 6
[post_date] => 2021-05-28 18:55:12
[post_date_gmt] => 2021-05-28 18:55:12
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:15
[post_modified_gmt] => 2021-08-23 10:02:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2965
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[202] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:17
[post_modified_gmt] => 2021-08-23 10:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[203] => WP_Post Object
(
[ID] => 2960
[post_author] => 6
[post_date] => 2021-05-28 18:53:36
[post_date_gmt] => 2021-05-28 18:53:36
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:20
[post_modified_gmt] => 2021-08-23 10:02:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2960
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[204] => WP_Post Object
(
[ID] => 2964
[post_author] => 6
[post_date] => 2021-05-28 18:53:11
[post_date_gmt] => 2021-05-28 18:53:11
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:24
[post_modified_gmt] => 2021-08-23 10:02:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2964
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[205] => WP_Post Object
(
[ID] => 2958
[post_author] => 6
[post_date] => 2021-05-28 18:52:54
[post_date_gmt] => 2021-05-28 18:52:54
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:13:48
[post_modified_gmt] => 2021-12-03 10:13:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2958
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[206] => WP_Post Object
(
[ID] => 2949
[post_author] => 6
[post_date] => 2021-05-28 18:52:06
[post_date_gmt] => 2021-05-28 18:52:06
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:37:55
[post_modified_gmt] => 2021-11-23 12:37:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2949
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[207] => WP_Post Object
(
[ID] => 2957
[post_author] => 6
[post_date] => 2021-05-28 18:51:39
[post_date_gmt] => 2021-05-28 18:51:39
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:00:44
[post_modified_gmt] => 2022-01-27 12:00:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2957
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[208] => WP_Post Object
(
[ID] => 2962
[post_author] => 6
[post_date] => 2021-05-28 18:50:18
[post_date_gmt] => 2021-05-28 18:50:18
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:38:17
[post_modified_gmt] => 2021-11-23 12:38:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2962
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[209] => WP_Post Object
(
[ID] => 2945
[post_author] => 6
[post_date] => 2021-05-28 14:03:27
[post_date_gmt] => 2021-05-28 14:03:27
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:13:02
[post_modified_gmt] => 2021-12-03 10:13:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2945
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[210] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:35:40
[post_modified_gmt] => 2022-02-28 08:35:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[211] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:59:23
[post_modified_gmt] => 2022-02-28 08:59:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[212] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 09:05:23
[post_modified_gmt] => 2022-02-28 09:05:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[213] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 09:23:17
[post_modified_gmt] => 2022-02-28 09:23:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[214] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:11:21
[post_modified_gmt] => 2022-04-01 10:11:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[215] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:45:33
[post_modified_gmt] => 2022-03-28 10:45:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[216] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 10:58:28
[post_modified_gmt] => 2022-02-28 10:58:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[217] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:01:15
[post_modified_gmt] => 2022-02-28 14:01:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[218] => WP_Post Object
(
[ID] => 2824
[post_author] => 5
[post_date] => 2021-04-16 16:39:49
[post_date_gmt] => 2021-04-16 16:39:49
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:31:21
[post_modified_gmt] => 2022-01-27 12:31:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2824
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[219] => WP_Post Object
(
[ID] => 2823
[post_author] => 5
[post_date] => 2021-04-16 16:17:11
[post_date_gmt] => 2021-04-16 16:17:11
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:36:43
[post_modified_gmt] => 2022-01-18 12:36:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2823
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[220] => WP_Post Object
(
[ID] => 2822
[post_author] => 5
[post_date] => 2021-04-16 16:09:31
[post_date_gmt] => 2021-04-16 16:09:31
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:48:13
[post_modified_gmt] => 2022-01-18 12:48:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2822
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[221] => WP_Post Object
(
[ID] => 2820
[post_author] => 5
[post_date] => 2021-04-16 12:44:14
[post_date_gmt] => 2021-04-16 12:44:14
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:50:08
[post_modified_gmt] => 2022-01-18 12:50:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2820
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[222] => WP_Post Object
(
[ID] => 2744
[post_author] => 5
[post_date] => 2021-03-30 15:12:35
[post_date_gmt] => 2021-03-30 15:12:35
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:48:08
[post_modified_gmt] => 2021-08-12 13:48:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[223] => WP_Post Object
(
[ID] => 2749
[post_author] => 5
[post_date] => 2021-03-30 15:10:16
[post_date_gmt] => 2021-03-30 15:10:16
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:54:16
[post_modified_gmt] => 2021-08-12 13:54:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[224] => WP_Post Object
(
[ID] => 2748
[post_author] => 5
[post_date] => 2021-03-30 15:05:46
[post_date_gmt] => 2021-03-30 15:05:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2748
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:52:39
[post_modified_gmt] => 2021-08-12 13:52:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[225] => WP_Post Object
(
[ID] => 2743
[post_author] => 5
[post_date] => 2021-03-24 15:11:40
[post_date_gmt] => 2021-03-24 15:11:40
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:33:45
[post_modified_gmt] => 2022-01-27 12:33:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[226] => WP_Post Object
(
[ID] => 2742
[post_author] => 5
[post_date] => 2021-03-24 13:37:07
[post_date_gmt] => 2021-03-24 13:37:07
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:28:13
[post_modified_gmt] => 2021-08-12 12:28:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2742
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[227] => WP_Post Object
(
[ID] => 2741
[post_author] => 5
[post_date] => 2021-03-24 13:32:55
[post_date_gmt] => 2021-03-24 13:32:55
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:06:52
[post_modified_gmt] => 2021-11-23 15:06:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[228] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:47:55
[post_modified_gmt] => 2022-03-28 10:47:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[229] => WP_Post Object
(
[ID] => 2737
[post_author] => 5
[post_date] => 2021-03-24 13:00:46
[post_date_gmt] => 2021-03-24 13:00:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:45:35
[post_modified_gmt] => 2021-08-12 12:45:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2737
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[230] => WP_Post Object
(
[ID] => 2736
[post_author] => 5
[post_date] => 2021-03-23 18:15:15
[post_date_gmt] => 2021-03-23 18:15:15
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:50:37
[post_modified_gmt] => 2021-12-03 14:50:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[231] => WP_Post Object
(
[ID] => 2734
[post_author] => 5
[post_date] => 2021-03-23 18:01:22
[post_date_gmt] => 2021-03-23 18:01:22
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 10:29:04
[post_modified_gmt] => 2021-09-03 10:29:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2734
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[232] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 18:43:53
[post_modified_gmt] => 2022-01-04 18:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[233] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 09:35:45
[post_modified_gmt] => 2022-01-05 09:35:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[234] => WP_Post Object
(
[ID] => 2541
[post_author] => 5
[post_date] => 2021-03-12 18:11:14
[post_date_gmt] => 2021-03-12 18:11:14
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:49:36
[post_modified_gmt] => 2022-01-05 10:49:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2541
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[235] => WP_Post Object
(
[ID] => 2542
[post_author] => 5
[post_date] => 2021-03-12 14:21:07
[post_date_gmt] => 2021-03-12 14:21:07
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:17:48
[post_modified_gmt] => 2022-01-05 10:17:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2542
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[236] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:10:55
[post_modified_gmt] => 2022-03-28 10:10:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[237] => WP_Post Object
(
[ID] => 2545
[post_author] => 5
[post_date] => 2021-03-12 14:14:38
[post_date_gmt] => 2021-03-12 14:14:38
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:14:28
[post_modified_gmt] => 2022-03-09 13:14:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2545
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[238] => WP_Post Object
(
[ID] => 2547
[post_author] => 5
[post_date] => 2021-03-12 13:58:55
[post_date_gmt] => 2021-03-12 13:58:55
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:38:40
[post_modified_gmt] => 2022-01-27 12:38:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2547
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[239] => WP_Post Object
(
[ID] => 2549
[post_author] => 5
[post_date] => 2021-03-12 13:50:41
[post_date_gmt] => 2021-03-12 13:50:41
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 08:48:43
[post_modified_gmt] => 2022-01-05 08:48:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[240] => WP_Post Object
(
[ID] => 2553
[post_author] => 5
[post_date] => 2021-03-12 13:47:42
[post_date_gmt] => 2021-03-12 13:47:42
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:59:58
[post_modified_gmt] => 2022-01-05 10:59:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2553
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[241] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 12:14:51
[post_modified_gmt] => 2021-09-03 12:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[242] => WP_Post Object
(
[ID] => 2461
[post_author] => 5
[post_date] => 2021-02-25 15:23:35
[post_date_gmt] => 2021-02-25 15:23:35
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:19:55
[post_modified_gmt] => 2021-08-24 08:19:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[243] => WP_Post Object
(
[ID] => 2462
[post_author] => 5
[post_date] => 2021-02-25 15:23:19
[post_date_gmt] => 2021-02-25 15:23:19
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 13:28:17
[post_modified_gmt] => 2021-09-03 13:28:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[244] => WP_Post Object
(
[ID] => 2463
[post_author] => 5
[post_date] => 2021-02-25 15:22:52
[post_date_gmt] => 2021-02-25 15:22:52
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 13:35:23
[post_modified_gmt] => 2021-09-03 13:35:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2463
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[245] => WP_Post Object
(
[ID] => 2464
[post_author] => 5
[post_date] => 2021-02-25 15:21:51
[post_date_gmt] => 2021-02-25 15:21:51
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:13:03
[post_modified_gmt] => 2021-11-23 15:13:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2464
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[246] => WP_Post Object
(
[ID] => 2465
[post_author] => 5
[post_date] => 2021-02-25 15:21:32
[post_date_gmt] => 2021-02-25 15:21:32
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:40:25
[post_modified_gmt] => 2022-01-27 12:40:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2465
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[247] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:50:01
[post_modified_gmt] => 2022-03-28 10:50:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[248] => WP_Post Object
(
[ID] => 2467
[post_author] => 5
[post_date] => 2021-02-25 15:20:15
[post_date_gmt] => 2021-02-25 15:20:15
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:15:33
[post_modified_gmt] => 2022-03-09 13:15:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[249] => WP_Post Object
(
[ID] => 2470
[post_author] => 5
[post_date] => 2021-01-25 13:24:13
[post_date_gmt] => 2021-01-25 13:24:13
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 13:54:22
[post_modified_gmt] => 2022-03-28 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2470
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[250] => WP_Post Object
(
[ID] => 2473
[post_author] => 5
[post_date] => 2021-01-25 13:21:58
[post_date_gmt] => 2021-01-25 13:21:58
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:14:59
[post_modified_gmt] => 2022-01-04 14:14:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2473
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[251] => WP_Post Object
(
[ID] => 2474
[post_author] => 5
[post_date] => 2021-01-25 13:19:34
[post_date_gmt] => 2021-01-25 13:19:34
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:54:44
[post_modified_gmt] => 2022-01-04 12:54:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2474
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[252] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 11:57:00
[post_modified_gmt] => 2022-01-04 11:57:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[253] => WP_Post Object
(
[ID] => 2476
[post_author] => 5
[post_date] => 2021-01-25 13:18:09
[post_date_gmt] => 2021-01-25 13:18:09
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:42:48
[post_modified_gmt] => 2022-01-04 12:42:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2476
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[254] => WP_Post Object
(
[ID] => 2477
[post_author] => 5
[post_date] => 2021-01-25 13:16:23
[post_date_gmt] => 2021-01-25 13:16:23
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:38:40
[post_modified_gmt] => 2022-03-08 13:38:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2477
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[255] => WP_Post Object
(
[ID] => 2479
[post_author] => 5
[post_date] => 2021-01-25 13:12:32
[post_date_gmt] => 2021-01-25 13:12:32
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:42:15
[post_modified_gmt] => 2022-01-27 12:42:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[256] => WP_Post Object
(
[ID] => 2481
[post_author] => 5
[post_date] => 2021-01-25 13:11:08
[post_date_gmt] => 2021-01-25 13:11:08
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 10:39:14
[post_modified_gmt] => 2022-01-19 10:39:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[257] => WP_Post Object
(
[ID] => 2482
[post_author] => 5
[post_date] => 2021-01-25 13:09:37
[post_date_gmt] => 2021-01-25 13:09:37
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:23:50
[post_modified_gmt] => 2022-01-04 14:23:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[258] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 13:51:57
[post_modified_gmt] => 2022-01-04 13:51:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[259] => WP_Post Object
(
[ID] => 2454
[post_author] => 5
[post_date] => 2021-01-19 11:44:16
[post_date_gmt] => 2021-01-19 11:44:16
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:28:26
[post_modified_gmt] => 2021-11-23 14:28:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2454
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[260] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:12:55
[post_modified_gmt] => 2022-03-28 10:12:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[261] => WP_Post Object
(
[ID] => 2450
[post_author] => 5
[post_date] => 2021-01-19 11:04:23
[post_date_gmt] => 2021-01-19 11:04:23
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:46:34
[post_modified_gmt] => 2022-01-27 12:46:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2450
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[262] => WP_Post Object
(
[ID] => 2449
[post_author] => 5
[post_date] => 2021-01-19 10:47:27
[post_date_gmt] => 2021-01-19 10:47:27
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:29:46
[post_modified_gmt] => 2021-11-23 14:29:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2449
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[263] => WP_Post Object
(
[ID] => 2448
[post_author] => 5
[post_date] => 2021-01-19 10:24:45
[post_date_gmt] => 2021-01-19 10:24:45
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:29:52
[post_modified_gmt] => 2021-11-23 14:29:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2448
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[264] => WP_Post Object
(
[ID] => 2444
[post_author] => 5
[post_date] => 2021-01-19 09:27:20
[post_date_gmt] => 2021-01-19 09:27:20
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:42:37
[post_modified_gmt] => 2022-03-08 13:42:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2444
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[265] => WP_Post Object
(
[ID] => 2443
[post_author] => 5
[post_date] => 2021-01-19 09:14:03
[post_date_gmt] => 2021-01-19 09:14:03
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:17:16
[post_modified_gmt] => 2021-11-23 14:17:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2443
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[266] => WP_Post Object
(
[ID] => 2442
[post_author] => 5
[post_date] => 2021-01-19 06:56:32
[post_date_gmt] => 2021-01-19 06:56:32
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-08 11:02:27
[post_modified_gmt] => 2021-12-08 11:02:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2442
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[267] => WP_Post Object
(
[ID] => 2441
[post_author] => 5
[post_date] => 2021-01-19 06:48:04
[post_date_gmt] => 2021-01-19 06:48:04
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:47:37
[post_modified_gmt] => 2022-01-27 12:47:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2441
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[268] => WP_Post Object
(
[ID] => 2426
[post_author] => 5
[post_date] => 2020-12-14 15:02:08
[post_date_gmt] => 2020-12-14 15:02:08
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:44:08
[post_modified_gmt] => 2021-12-07 11:44:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[269] => WP_Post Object
(
[ID] => 2424
[post_author] => 5
[post_date] => 2020-12-14 15:01:40
[post_date_gmt] => 2020-12-14 15:01:40
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:46:03
[post_modified_gmt] => 2021-11-23 12:46:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[270] => WP_Post Object
(
[ID] => 3909
[post_author] => 5
[post_date] => 2021-11-22 13:29:28
[post_date_gmt] => 2021-11-22 13:29:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:13:09
[post_modified_gmt] => 2022-03-09 11:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[271] => WP_Post Object
(
[ID] => 3908
[post_author] => 5
[post_date] => 2021-11-22 13:20:09
[post_date_gmt] => 2021-11-22 13:20:09
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:28:33
[post_modified_gmt] => 2022-02-11 13:28:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[272] => WP_Post Object
(
[ID] => 3906
[post_author] => 5
[post_date] => 2021-11-22 12:57:50
[post_date_gmt] => 2021-11-22 12:57:50
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:22:44
[post_modified_gmt] => 2022-01-31 15:22:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[273] => WP_Post Object
(
[ID] => 3904
[post_author] => 5
[post_date] => 2021-11-22 12:20:20
[post_date_gmt] => 2021-11-22 12:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:00
[post_modified_gmt] => 2022-01-31 15:23:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3904
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[274] => WP_Post Object
(
[ID] => 3903
[post_author] => 5
[post_date] => 2021-11-22 12:04:07
[post_date_gmt] => 2021-11-22 12:04:07
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:16
[post_modified_gmt] => 2022-01-31 15:23:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3903
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[275] => WP_Post Object
(
[ID] => 3901
[post_author] => 5
[post_date] => 2021-11-22 11:42:55
[post_date_gmt] => 2021-11-22 11:42:55
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:34
[post_modified_gmt] => 2022-01-31 15:23:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3901
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[276] => WP_Post Object
(
[ID] => 3900
[post_author] => 5
[post_date] => 2021-11-22 11:35:10
[post_date_gmt] => 2021-11-22 11:35:10
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:52
[post_modified_gmt] => 2022-01-31 15:23:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3900
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[277] => WP_Post Object
(
[ID] => 3899
[post_author] => 5
[post_date] => 2021-11-22 11:24:36
[post_date_gmt] => 2021-11-22 11:24:36
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:42:51
[post_modified_gmt] => 2022-03-21 13:42:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3899
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[278] => WP_Post Object
(
[ID] => 3898
[post_author] => 5
[post_date] => 2021-11-22 11:02:44
[post_date_gmt] => 2021-11-22 11:02:44
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:24:53
[post_modified_gmt] => 2022-01-31 15:24:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3898
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[279] => WP_Post Object
(
[ID] => 3897
[post_author] => 5
[post_date] => 2021-11-22 10:34:34
[post_date_gmt] => 2021-11-22 10:34:34
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:11
[post_modified_gmt] => 2022-01-31 15:25:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3897
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[280] => WP_Post Object
(
[ID] => 3896
[post_author] => 5
[post_date] => 2021-11-22 10:27:28
[post_date_gmt] => 2021-11-22 10:27:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:40
[post_modified_gmt] => 2022-01-31 15:25:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3896
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[281] => WP_Post Object
(
[ID] => 3895
[post_author] => 5
[post_date] => 2021-11-22 10:20:20
[post_date_gmt] => 2021-11-22 10:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 09:51:43
[post_modified_gmt] => 2022-04-01 09:51:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3895
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[282] => WP_Post Object
(
[ID] => 3892
[post_author] => 5
[post_date] => 2021-11-19 13:53:26
[post_date_gmt] => 2021-11-19 13:53:26
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:26:44
[post_modified_gmt] => 2022-01-31 15:26:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[283] => WP_Post Object
(
[ID] => 3891
[post_author] => 5
[post_date] => 2021-11-19 13:11:12
[post_date_gmt] => 2021-11-19 13:11:12
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:27:01
[post_modified_gmt] => 2022-01-31 15:27:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3891
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[284] => WP_Post Object
(
[ID] => 3890
[post_author] => 5
[post_date] => 2021-11-19 13:00:24
[post_date_gmt] => 2021-11-19 13:00:24
[post_content] =>
[post_title] => MSD - MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:27:21
[post_modified_gmt] => 2022-01-31 15:27:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[285] => WP_Post Object
(
[ID] => 3418
[post_author] => 5
[post_date] => 2021-06-30 19:06:19
[post_date_gmt] => 2021-06-30 19:06:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:03:49
[post_modified_gmt] => 2022-03-09 13:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3418
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[286] => WP_Post Object
(
[ID] => 3417
[post_author] => 5
[post_date] => 2021-06-30 19:04:34
[post_date_gmt] => 2021-06-30 19:04:34
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:39
[post_modified_gmt] => 2021-09-01 15:12:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3417
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[287] => WP_Post Object
(
[ID] => 3416
[post_author] => 5
[post_date] => 2021-06-30 19:02:19
[post_date_gmt] => 2021-06-30 19:02:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:57
[post_modified_gmt] => 2021-09-01 15:12:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3416
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[288] => WP_Post Object
(
[ID] => 3415
[post_author] => 5
[post_date] => 2021-06-30 19:00:20
[post_date_gmt] => 2021-06-30 19:00:20
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 12:40:36
[post_modified_gmt] => 2021-11-30 12:40:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3415
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[289] => WP_Post Object
(
[ID] => 3414
[post_author] => 5
[post_date] => 2021-06-30 18:54:43
[post_date_gmt] => 2021-06-30 18:54:43
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:08:59
[post_modified_gmt] => 2021-09-01 15:08:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3414
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[290] => WP_Post Object
(
[ID] => 3413
[post_author] => 5
[post_date] => 2021-06-30 18:52:08
[post_date_gmt] => 2021-06-30 18:52:08
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:10:41
[post_modified_gmt] => 2021-09-01 15:10:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3413
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[291] => WP_Post Object
(
[ID] => 3412
[post_author] => 5
[post_date] => 2021-06-30 18:48:13
[post_date_gmt] => 2021-06-30 18:48:13
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:32:40
[post_modified_gmt] => 2022-02-11 13:32:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3412
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[292] => WP_Post Object
(
[ID] => 3411
[post_author] => 5
[post_date] => 2021-06-30 18:39:53
[post_date_gmt] => 2021-06-30 18:39:53
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:11:28
[post_modified_gmt] => 2021-09-01 15:11:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3411
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[293] => WP_Post Object
(
[ID] => 3410
[post_author] => 5
[post_date] => 2021-06-30 18:37:02
[post_date_gmt] => 2021-06-30 18:37:02
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:09:38
[post_modified_gmt] => 2021-09-01 15:09:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3410
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[294] => WP_Post Object
(
[ID] => 3409
[post_author] => 5
[post_date] => 2021-06-30 18:34:04
[post_date_gmt] => 2021-06-30 18:34:04
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:58:15
[post_modified_gmt] => 2022-01-24 12:58:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3409
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[295] => WP_Post Object
(
[ID] => 3406
[post_author] => 5
[post_date] => 2021-06-30 18:25:58
[post_date_gmt] => 2021-06-30 18:25:58
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:11:44
[post_modified_gmt] => 2021-09-01 15:11:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3406
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[296] => WP_Post Object
(
[ID] => 3304
[post_author] => 6
[post_date] => 2021-06-30 09:30:56
[post_date_gmt] => 2021-06-30 09:30:56
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:21
[post_modified_gmt] => 2021-08-23 10:01:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[297] => WP_Post Object
(
[ID] => 2873
[post_author] => 6
[post_date] => 2021-05-11 15:17:08
[post_date_gmt] => 2021-05-11 15:17:08
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:50:47
[post_modified_gmt] => 2021-11-22 15:50:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[298] => WP_Post Object
(
[ID] => 2872
[post_author] => 6
[post_date] => 2021-05-11 15:14:24
[post_date_gmt] => 2021-05-11 15:14:24
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:00:31
[post_modified_gmt] => 2021-12-06 12:00:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2872
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[299] => WP_Post Object
(
[ID] => 2870
[post_author] => 6
[post_date] => 2021-05-11 15:07:59
[post_date_gmt] => 2021-05-11 15:07:59
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-15 09:15:21
[post_modified_gmt] => 2021-06-15 09:15:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[300] => WP_Post Object
(
[ID] => 2869
[post_author] => 6
[post_date] => 2021-05-11 14:53:04
[post_date_gmt] => 2021-05-11 14:53:04
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:15:00
[post_modified_gmt] => 2021-05-14 09:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[301] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 12:12:41
[post_modified_gmt] => 2022-05-24 12:12:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 302
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:09:54
[post_modified_gmt] => 2022-05-24 09:09:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 302
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => b1050dec43e5eb51fb39662feaeb2b86
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:09:54
[post_modified_gmt] => 2022-05-24 09:09:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4807
[post_author] => 5
[post_date] => 2022-05-24 09:02:55
[post_date_gmt] => 2022-05-24 09:02:55
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:02:55
[post_modified_gmt] => 2022-05-24 09:02:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4806
[post_author] => 5
[post_date] => 2022-05-24 08:59:08
[post_date_gmt] => 2022-05-24 08:59:08
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:08
[post_modified_gmt] => 2022-05-24 08:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4805
[post_author] => 5
[post_date] => 2022-05-24 08:53:12
[post_date_gmt] => 2022-05-24 08:53:12
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:42
[post_modified_gmt] => 2022-05-24 08:59:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4804
[post_author] => 5
[post_date] => 2022-05-24 08:40:15
[post_date_gmt] => 2022-05-24 08:40:15
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:53:51
[post_modified_gmt] => 2022-05-24 08:53:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 4802
[post_author] => 5
[post_date] => 2022-05-24 08:24:23
[post_date_gmt] => 2022-05-24 08:24:23
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:24:23
[post_modified_gmt] => 2022-05-24 08:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 4801
[post_author] => 5
[post_date] => 2022-05-24 08:19:21
[post_date_gmt] => 2022-05-24 08:19:21
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:19:21
[post_modified_gmt] => 2022-05-24 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 4800
[post_author] => 5
[post_date] => 2022-05-24 08:07:39
[post_date_gmt] => 2022-05-24 08:07:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:08:30
[post_modified_gmt] => 2022-05-24 08:08:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 4797
[post_author] => 5
[post_date] => 2022-05-23 13:54:57
[post_date_gmt] => 2022-05-23 13:54:57
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 13:54:57
[post_modified_gmt] => 2022-05-23 13:54:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 4796
[post_author] => 5
[post_date] => 2022-05-23 13:54:05
[post_date_gmt] => 2022-05-23 13:54:05
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:21:34
[post_modified_gmt] => 2022-05-23 14:21:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 4661
[post_author] => 5
[post_date] => 2022-04-20 08:13:06
[post_date_gmt] => 2022-04-20 08:13:06
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:13:06
[post_modified_gmt] => 2022-04-20 08:13:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4661
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:22:54
[post_modified_gmt] => 2022-04-18 13:22:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 4601
[post_author] => 5
[post_date] => 2022-04-18 10:40:48
[post_date_gmt] => 2022-04-18 10:40:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:44:46
[post_modified_gmt] => 2022-04-18 10:44:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4601
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:55:19
[post_modified_gmt] => 2022-04-18 13:55:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 4223
[post_author] => 5
[post_date] => 2022-03-04 09:43:58
[post_date_gmt] => 2022-03-04 09:43:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 09:43:58
[post_modified_gmt] => 2022-03-04 09:43:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 4222
[post_author] => 5
[post_date] => 2022-03-04 09:14:41
[post_date_gmt] => 2022-03-04 09:14:41
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:51:38
[post_modified_gmt] => 2022-03-08 13:51:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 4221
[post_author] => 5
[post_date] => 2022-03-04 09:05:29
[post_date_gmt] => 2022-03-04 09:05:29
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 09:05:29
[post_modified_gmt] => 2022-03-04 09:05:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 4220
[post_author] => 5
[post_date] => 2022-03-04 08:47:04
[post_date_gmt] => 2022-03-04 08:47:04
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 08:47:04
[post_modified_gmt] => 2022-03-04 08:47:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 4219
[post_author] => 5
[post_date] => 2022-03-04 08:02:15
[post_date_gmt] => 2022-03-04 08:02:15
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 08:47:42
[post_modified_gmt] => 2022-03-04 08:47:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 4218
[post_author] => 5
[post_date] => 2022-03-03 14:17:53
[post_date_gmt] => 2022-03-03 14:17:53
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 14:17:53
[post_modified_gmt] => 2022-03-03 14:17:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 4217
[post_author] => 5
[post_date] => 2022-03-03 13:59:58
[post_date_gmt] => 2022-03-03 13:59:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 14:11:50
[post_modified_gmt] => 2022-03-03 14:11:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 4216
[post_author] => 5
[post_date] => 2022-03-03 13:45:21
[post_date_gmt] => 2022-03-03 13:45:21
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 13:45:46
[post_modified_gmt] => 2022-03-03 13:45:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 4215
[post_author] => 5
[post_date] => 2022-03-03 13:31:56
[post_date_gmt] => 2022-03-03 13:31:56
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 13:42:58
[post_modified_gmt] => 2022-03-03 13:42:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:17:07
[post_modified_gmt] => 2022-03-21 13:17:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-03 10:58:00
[post_modified_gmt] => 2022-03-03 10:58:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 4212
[post_author] => 5
[post_date] => 2022-03-02 14:54:16
[post_date_gmt] => 2022-03-02 14:54:16
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:51:03
[post_modified_gmt] => 2022-03-08 13:51:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4212
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 4210
[post_author] => 5
[post_date] => 2022-03-02 13:14:31
[post_date_gmt] => 2022-03-02 13:14:31
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-02 13:14:31
[post_modified_gmt] => 2022-03-02 13:14:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 4209
[post_author] => 5
[post_date] => 2022-03-02 12:07:13
[post_date_gmt] => 2022-03-02 12:07:13
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-04 10:05:30
[post_modified_gmt] => 2022-03-04 10:05:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4209
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 4205
[post_author] => 5
[post_date] => 2022-02-28 15:24:19
[post_date_gmt] => 2022-02-28 15:24:19
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 15:24:19
[post_modified_gmt] => 2022-02-28 15:24:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 4204
[post_author] => 5
[post_date] => 2022-02-28 14:53:11
[post_date_gmt] => 2022-02-28 14:53:11
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:53:11
[post_modified_gmt] => 2022-02-28 14:53:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 4201
[post_author] => 5
[post_date] => 2022-02-28 13:33:22
[post_date_gmt] => 2022-02-28 13:33:22
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:46:09
[post_modified_gmt] => 2022-02-28 14:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 4200
[post_author] => 5
[post_date] => 2022-02-28 13:13:29
[post_date_gmt] => 2022-02-28 13:13:29
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:54:57
[post_modified_gmt] => 2022-03-08 13:54:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:17:00
[post_modified_gmt] => 2022-04-18 13:17:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 4159
[post_author] => 5
[post_date] => 2022-02-02 13:10:48
[post_date_gmt] => 2022-02-02 13:10:48
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:16:05
[post_modified_gmt] => 2022-04-18 13:16:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 4158
[post_author] => 5
[post_date] => 2022-02-02 13:00:08
[post_date_gmt] => 2022-02-02 13:00:08
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:15:30
[post_modified_gmt] => 2022-04-18 13:15:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 4157
[post_author] => 5
[post_date] => 2022-02-02 12:54:56
[post_date_gmt] => 2022-02-02 12:54:56
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:13:37
[post_modified_gmt] => 2022-04-18 13:13:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 4156
[post_author] => 5
[post_date] => 2022-02-02 12:36:42
[post_date_gmt] => 2022-02-02 12:36:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:51
[post_modified_gmt] => 2022-04-18 13:12:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 4155
[post_author] => 5
[post_date] => 2022-02-02 12:19:16
[post_date_gmt] => 2022-02-02 12:19:16
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:26
[post_modified_gmt] => 2022-04-18 13:12:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 4154
[post_author] => 5
[post_date] => 2022-02-02 12:13:41
[post_date_gmt] => 2022-02-02 12:13:41
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 12:13:41
[post_modified_gmt] => 2022-02-02 12:13:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4154
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 4153
[post_author] => 5
[post_date] => 2022-02-02 12:10:13
[post_date_gmt] => 2022-02-02 12:10:13
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:02:30
[post_modified_gmt] => 2022-04-18 13:02:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4153
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 4152
[post_author] => 5
[post_date] => 2022-02-02 11:51:54
[post_date_gmt] => 2022-02-02 11:51:54
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:02:06
[post_modified_gmt] => 2022-04-18 13:02:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 4151
[post_author] => 5
[post_date] => 2022-02-02 11:39:24
[post_date_gmt] => 2022-02-02 11:39:24
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:35
[post_modified_gmt] => 2022-04-18 13:01:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:03
[post_modified_gmt] => 2022-04-18 13:01:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:00:34
[post_modified_gmt] => 2022-04-18 13:00:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 4146
[post_author] => 5
[post_date] => 2022-02-02 07:28:42
[post_date_gmt] => 2022-02-02 07:28:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 12:57:05
[post_modified_gmt] => 2022-04-18 12:57:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4146
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 4141
[post_author] => 5
[post_date] => 2022-01-31 14:31:23
[post_date_gmt] => 2022-01-31 14:31:23
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:33:23
[post_modified_gmt] => 2022-01-31 14:33:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 4140
[post_author] => 5
[post_date] => 2022-01-31 14:22:03
[post_date_gmt] => 2022-01-31 14:22:03
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:11:05
[post_modified_gmt] => 2022-03-09 13:11:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 4139
[post_author] => 5
[post_date] => 2022-01-31 14:18:32
[post_date_gmt] => 2022-01-31 14:18:32
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 11:35:27
[post_modified_gmt] => 2022-02-11 11:35:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 4138
[post_author] => 5
[post_date] => 2022-01-31 14:09:33
[post_date_gmt] => 2022-01-31 14:09:33
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:09:33
[post_modified_gmt] => 2022-01-31 14:09:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4138
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 4137
[post_author] => 5
[post_date] => 2022-01-31 13:53:37
[post_date_gmt] => 2022-01-31 13:53:37
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:54:45
[post_modified_gmt] => 2022-01-31 13:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 4136
[post_author] => 5
[post_date] => 2022-01-31 13:42:47
[post_date_gmt] => 2022-01-31 13:42:47
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:42:47
[post_modified_gmt] => 2022-01-31 13:42:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 4135
[post_author] => 5
[post_date] => 2022-01-31 13:25:08
[post_date_gmt] => 2022-01-31 13:25:08
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:25:08
[post_modified_gmt] => 2022-01-31 13:25:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 4134
[post_author] => 5
[post_date] => 2022-01-31 12:56:28
[post_date_gmt] => 2022-01-31 12:56:28
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:56:28
[post_modified_gmt] => 2022-01-31 12:56:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:24:36
[post_modified_gmt] => 2022-01-31 12:24:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 16:31:13
[post_modified_gmt] => 2022-01-29 16:31:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 4130
[post_author] => 5
[post_date] => 2022-01-29 15:34:50
[post_date_gmt] => 2022-01-29 15:34:50
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 15:49:57
[post_modified_gmt] => 2022-01-29 15:49:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4129
[post_author] => 5
[post_date] => 2022-01-28 14:43:06
[post_date_gmt] => 2022-01-28 14:43:06
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-31 16:21:05
[post_modified_gmt] => 2022-03-31 16:21:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:45:11
[post_modified_gmt] => 2022-01-28 13:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4058
[post_author] => 5
[post_date] => 2022-01-04 14:25:52
[post_date_gmt] => 2022-01-04 14:25:52
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:25:52
[post_modified_gmt] => 2022-01-04 14:25:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4058
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 4054
[post_author] => 5
[post_date] => 2022-01-03 11:45:52
[post_date_gmt] => 2022-01-03 11:45:52
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 11:46:09
[post_modified_gmt] => 2022-01-03 11:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4054
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 4051
[post_author] => 5
[post_date] => 2022-01-03 11:01:41
[post_date_gmt] => 2022-01-03 11:01:41
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 10:37:08
[post_modified_gmt] => 2022-03-09 10:37:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 4050
[post_author] => 5
[post_date] => 2022-01-03 10:49:32
[post_date_gmt] => 2022-01-03 10:49:32
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:56:55
[post_modified_gmt] => 2022-01-03 10:56:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4050
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 4047
[post_author] => 5
[post_date] => 2021-12-27 17:17:36
[post_date_gmt] => 2021-12-27 17:17:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:43:10
[post_modified_gmt] => 2022-01-03 10:43:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4047
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 4046
[post_author] => 5
[post_date] => 2021-12-27 17:10:47
[post_date_gmt] => 2021-12-27 17:10:47
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:10:47
[post_modified_gmt] => 2021-12-27 17:10:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4046
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 4045
[post_author] => 5
[post_date] => 2021-12-27 17:07:25
[post_date_gmt] => 2021-12-27 17:07:25
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:07:25
[post_modified_gmt] => 2021-12-27 17:07:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4045
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 4043
[post_author] => 5
[post_date] => 2021-12-27 16:47:54
[post_date_gmt] => 2021-12-27 16:47:54
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:47:54
[post_modified_gmt] => 2021-12-27 16:47:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4043
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 4042
[post_author] => 5
[post_date] => 2021-12-27 16:41:56
[post_date_gmt] => 2021-12-27 16:41:56
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 10:56:31
[post_modified_gmt] => 2022-01-27 10:56:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4042
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 4041
[post_author] => 5
[post_date] => 2021-12-27 16:28:21
[post_date_gmt] => 2021-12-27 16:28:21
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:28:42
[post_modified_gmt] => 2021-12-27 16:28:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4041
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 4040
[post_author] => 5
[post_date] => 2021-12-27 15:24:04
[post_date_gmt] => 2021-12-27 15:24:04
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-14 12:58:21
[post_modified_gmt] => 2022-03-14 12:58:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 4038
[post_author] => 5
[post_date] => 2021-12-27 15:08:30
[post_date_gmt] => 2021-12-27 15:08:30
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:22:28
[post_modified_gmt] => 2022-01-24 12:22:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4038
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 4036
[post_author] => 5
[post_date] => 2021-12-26 17:01:45
[post_date_gmt] => 2021-12-26 17:01:45
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:22:53
[post_modified_gmt] => 2022-02-11 13:22:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4036
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 4035
[post_author] => 5
[post_date] => 2021-12-26 16:47:36
[post_date_gmt] => 2021-12-26 16:47:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-26 16:47:36
[post_modified_gmt] => 2021-12-26 16:47:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4035
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 4032
[post_author] => 5
[post_date] => 2021-12-26 16:32:27
[post_date_gmt] => 2021-12-26 16:32:27
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-22 14:37:29
[post_modified_gmt] => 2022-01-22 14:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4032
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 4029
[post_author] => 5
[post_date] => 2021-12-21 12:22:08
[post_date_gmt] => 2021-12-21 12:22:08
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:10:58
[post_modified_gmt] => 2022-01-24 12:10:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4029
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 4028
[post_author] => 5
[post_date] => 2021-12-21 11:55:28
[post_date_gmt] => 2021-12-21 11:55:28
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-21 11:56:51
[post_modified_gmt] => 2021-12-21 11:56:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4028
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 4024
[post_author] => 5
[post_date] => 2021-12-15 15:33:17
[post_date_gmt] => 2021-12-15 15:33:17
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 15:33:17
[post_modified_gmt] => 2021-12-15 15:33:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4024
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 4022
[post_author] => 5
[post_date] => 2021-12-15 14:49:36
[post_date_gmt] => 2021-12-15 14:49:36
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:51:23
[post_modified_gmt] => 2021-12-15 14:51:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4022
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 4021
[post_author] => 5
[post_date] => 2021-12-15 14:31:00
[post_date_gmt] => 2021-12-15 14:31:00
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:31:00
[post_modified_gmt] => 2021-12-15 14:31:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4021
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 4020
[post_author] => 5
[post_date] => 2021-12-15 14:24:47
[post_date_gmt] => 2021-12-15 14:24:47
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:24:47
[post_modified_gmt] => 2021-12-15 14:24:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4020
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 4017
[post_author] => 5
[post_date] => 2021-12-15 13:22:49
[post_date_gmt] => 2021-12-15 13:22:49
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 13:22:49
[post_modified_gmt] => 2021-12-15 13:22:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4017
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 4016
[post_author] => 5
[post_date] => 2021-12-15 13:20:07
[post_date_gmt] => 2021-12-15 13:20:07
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:34:02
[post_modified_gmt] => 2022-01-27 11:34:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4016
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 4014
[post_author] => 5
[post_date] => 2021-12-15 12:33:09
[post_date_gmt] => 2021-12-15 12:33:09
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:33:09
[post_modified_gmt] => 2021-12-15 12:33:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4014
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 4013
[post_author] => 5
[post_date] => 2021-12-15 12:16:20
[post_date_gmt] => 2021-12-15 12:16:20
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:17:01
[post_modified_gmt] => 2021-12-15 12:17:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4013
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 4012
[post_author] => 5
[post_date] => 2021-12-15 12:01:13
[post_date_gmt] => 2021-12-15 12:01:13
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:01:13
[post_modified_gmt] => 2021-12-15 12:01:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4012
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 4011
[post_author] => 5
[post_date] => 2021-12-14 15:21:54
[post_date_gmt] => 2021-12-14 15:21:54
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 11:48:20
[post_modified_gmt] => 2021-12-15 11:48:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4011
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 4009
[post_author] => 5
[post_date] => 2021-12-14 15:10:51
[post_date_gmt] => 2021-12-14 15:10:51
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:00:07
[post_modified_gmt] => 2022-03-09 11:00:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4009
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 4007
[post_author] => 5
[post_date] => 2021-12-14 08:51:32
[post_date_gmt] => 2021-12-14 08:51:32
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 08:51:44
[post_modified_gmt] => 2021-12-14 08:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4007
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 4006
[post_author] => 5
[post_date] => 2021-12-14 08:16:01
[post_date_gmt] => 2021-12-14 08:16:01
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 14:46:11
[post_modified_gmt] => 2022-03-23 14:46:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4006
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 4004
[post_author] => 5
[post_date] => 2021-12-14 07:57:41
[post_date_gmt] => 2021-12-14 07:57:41
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 07:57:41
[post_modified_gmt] => 2021-12-14 07:57:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4004
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 4003
[post_author] => 5
[post_date] => 2021-12-13 18:36:53
[post_date_gmt] => 2021-12-13 18:36:53
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:25:43
[post_modified_gmt] => 2022-02-11 13:25:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4003
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 4002
[post_author] => 5
[post_date] => 2021-12-13 18:28:05
[post_date_gmt] => 2021-12-13 18:28:05
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:41:28
[post_modified_gmt] => 2021-12-13 18:41:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4002
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 4001
[post_author] => 5
[post_date] => 2021-12-13 14:55:46
[post_date_gmt] => 2021-12-13 14:55:46
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:30:22
[post_modified_gmt] => 2021-12-13 18:30:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4001
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 3997
[post_author] => 5
[post_date] => 2021-12-13 14:24:49
[post_date_gmt] => 2021-12-13 14:24:49
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 14:24:59
[post_modified_gmt] => 2021-12-13 14:24:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3997
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 3909
[post_author] => 5
[post_date] => 2021-11-22 13:29:28
[post_date_gmt] => 2021-11-22 13:29:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:13:09
[post_modified_gmt] => 2022-03-09 11:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 3908
[post_author] => 5
[post_date] => 2021-11-22 13:20:09
[post_date_gmt] => 2021-11-22 13:20:09
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:28:33
[post_modified_gmt] => 2022-02-11 13:28:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 3906
[post_author] => 5
[post_date] => 2021-11-22 12:57:50
[post_date_gmt] => 2021-11-22 12:57:50
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:22:44
[post_modified_gmt] => 2022-01-31 15:22:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 3904
[post_author] => 5
[post_date] => 2021-11-22 12:20:20
[post_date_gmt] => 2021-11-22 12:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:00
[post_modified_gmt] => 2022-01-31 15:23:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3904
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 3903
[post_author] => 5
[post_date] => 2021-11-22 12:04:07
[post_date_gmt] => 2021-11-22 12:04:07
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:16
[post_modified_gmt] => 2022-01-31 15:23:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3903
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 3901
[post_author] => 5
[post_date] => 2021-11-22 11:42:55
[post_date_gmt] => 2021-11-22 11:42:55
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:34
[post_modified_gmt] => 2022-01-31 15:23:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3901
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 3900
[post_author] => 5
[post_date] => 2021-11-22 11:35:10
[post_date_gmt] => 2021-11-22 11:35:10
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:52
[post_modified_gmt] => 2022-01-31 15:23:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3900
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 3899
[post_author] => 5
[post_date] => 2021-11-22 11:24:36
[post_date_gmt] => 2021-11-22 11:24:36
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:42:51
[post_modified_gmt] => 2022-03-21 13:42:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3899
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 3898
[post_author] => 5
[post_date] => 2021-11-22 11:02:44
[post_date_gmt] => 2021-11-22 11:02:44
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:24:53
[post_modified_gmt] => 2022-01-31 15:24:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3898
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 3897
[post_author] => 5
[post_date] => 2021-11-22 10:34:34
[post_date_gmt] => 2021-11-22 10:34:34
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:11
[post_modified_gmt] => 2022-01-31 15:25:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3897
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 3896
[post_author] => 5
[post_date] => 2021-11-22 10:27:28
[post_date_gmt] => 2021-11-22 10:27:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:40
[post_modified_gmt] => 2022-01-31 15:25:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3896
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 3895
[post_author] => 5
[post_date] => 2021-11-22 10:20:20
[post_date_gmt] => 2021-11-22 10:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 09:51:43
[post_modified_gmt] => 2022-04-01 09:51:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3895
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 3892
[post_author] => 5
[post_date] => 2021-11-19 13:53:26
[post_date_gmt] => 2021-11-19 13:53:26
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:26:44
[post_modified_gmt] => 2022-01-31 15:26:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 3891
[post_author] => 5
[post_date] => 2021-11-19 13:11:12
[post_date_gmt] => 2021-11-19 13:11:12
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:27:01
[post_modified_gmt] => 2022-01-31 15:27:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3891
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 3890
[post_author] => 5
[post_date] => 2021-11-19 13:00:24
[post_date_gmt] => 2021-11-19 13:00:24
[post_content] =>
[post_title] => MSD - MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:27:21
[post_modified_gmt] => 2022-01-31 15:27:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 3869
[post_author] => 5
[post_date] => 2021-11-19 12:55:06
[post_date_gmt] => 2021-11-19 12:55:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-02 15:02:14
[post_modified_gmt] => 2021-12-02 15:02:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 3886
[post_author] => 5
[post_date] => 2021-11-18 16:36:37
[post_date_gmt] => 2021-11-18 16:36:37
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 06:09:26
[post_modified_gmt] => 2022-04-12 06:09:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3886
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 3884
[post_author] => 5
[post_date] => 2021-11-18 16:17:51
[post_date_gmt] => 2021-11-18 16:17:51
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:17:21
[post_modified_gmt] => 2022-03-09 11:17:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3884
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 3883
[post_author] => 5
[post_date] => 2021-11-18 16:10:24
[post_date_gmt] => 2021-11-18 16:10:24
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:48:26
[post_modified_gmt] => 2021-12-03 12:48:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3883
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 3882
[post_author] => 5
[post_date] => 2021-11-18 16:01:06
[post_date_gmt] => 2021-11-18 16:01:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:49:07
[post_modified_gmt] => 2021-12-03 12:49:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3882
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 3881
[post_author] => 5
[post_date] => 2021-11-18 15:52:45
[post_date_gmt] => 2021-11-18 15:52:45
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:52:45
[post_modified_gmt] => 2021-11-18 15:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3881
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 3880
[post_author] => 5
[post_date] => 2021-11-18 15:50:26
[post_date_gmt] => 2021-11-18 15:50:26
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:50:26
[post_modified_gmt] => 2021-11-18 15:50:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3880
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 3878
[post_author] => 5
[post_date] => 2021-11-18 15:08:19
[post_date_gmt] => 2021-11-18 15:08:19
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:08:19
[post_modified_gmt] => 2021-11-18 15:08:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3878
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 3877
[post_author] => 5
[post_date] => 2021-11-18 15:05:16
[post_date_gmt] => 2021-11-18 15:05:16
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:39:09
[post_modified_gmt] => 2022-01-27 11:39:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 3876
[post_author] => 5
[post_date] => 2021-11-18 14:51:40
[post_date_gmt] => 2021-11-18 14:51:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 14:51:40
[post_modified_gmt] => 2021-11-18 14:51:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3876
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 3875
[post_author] => 5
[post_date] => 2021-11-18 14:43:39
[post_date_gmt] => 2021-11-18 14:43:39
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 10:50:23
[post_modified_gmt] => 2021-11-22 10:50:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3875
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 3874
[post_author] => 5
[post_date] => 2021-11-18 14:29:06
[post_date_gmt] => 2021-11-18 14:29:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 08:08:10
[post_modified_gmt] => 2022-04-12 08:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3874
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 3873
[post_author] => 5
[post_date] => 2021-11-18 14:05:12
[post_date_gmt] => 2021-11-18 14:05:12
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:22:45
[post_modified_gmt] => 2021-11-19 12:22:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 3870
[post_author] => 5
[post_date] => 2021-11-18 12:58:35
[post_date_gmt] => 2021-11-18 12:58:35
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:25:29
[post_modified_gmt] => 2021-11-19 12:25:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 3863
[post_author] => 5
[post_date] => 2021-11-05 14:19:38
[post_date_gmt] => 2021-11-05 14:19:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:42
[post_modified_gmt] => 2022-04-18 09:22:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3863
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 3861
[post_author] => 5
[post_date] => 2021-11-05 13:59:54
[post_date_gmt] => 2021-11-05 13:59:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:26
[post_modified_gmt] => 2022-04-18 07:16:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3861
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 3860
[post_author] => 5
[post_date] => 2021-11-05 13:51:48
[post_date_gmt] => 2021-11-05 13:51:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:48
[post_modified_gmt] => 2022-04-18 07:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3860
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 3859
[post_author] => 5
[post_date] => 2021-11-05 13:44:47
[post_date_gmt] => 2021-11-05 13:44:47
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:28:57
[post_modified_gmt] => 2022-04-18 07:28:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3859
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 3858
[post_author] => 5
[post_date] => 2021-11-05 13:39:37
[post_date_gmt] => 2021-11-05 13:39:37
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:54:11
[post_modified_gmt] => 2022-04-18 07:54:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3858
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 3857
[post_author] => 5
[post_date] => 2021-11-05 13:37:12
[post_date_gmt] => 2021-11-05 13:37:12
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:41:41
[post_modified_gmt] => 2022-04-18 07:41:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3857
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 3856
[post_author] => 5
[post_date] => 2021-11-05 13:12:38
[post_date_gmt] => 2021-11-05 13:12:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:11:42
[post_modified_gmt] => 2022-04-18 08:11:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3856
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 3855
[post_author] => 5
[post_date] => 2021-11-05 13:10:25
[post_date_gmt] => 2021-11-05 13:10:25
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:05:19
[post_modified_gmt] => 2022-04-18 08:05:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3855
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 3854
[post_author] => 5
[post_date] => 2021-11-05 13:03:41
[post_date_gmt] => 2021-11-05 13:03:41
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:15:00
[post_modified_gmt] => 2022-04-18 08:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3854
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 3852
[post_author] => 5
[post_date] => 2021-11-05 12:43:57
[post_date_gmt] => 2021-11-05 12:43:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:33:20
[post_modified_gmt] => 2022-04-18 08:33:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3852
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 3851
[post_author] => 5
[post_date] => 2021-11-05 12:41:54
[post_date_gmt] => 2021-11-05 12:41:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:45:20
[post_modified_gmt] => 2022-04-18 08:45:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3851
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 3849
[post_author] => 5
[post_date] => 2021-11-05 12:30:09
[post_date_gmt] => 2021-11-05 12:30:09
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:52:12
[post_modified_gmt] => 2022-04-18 08:52:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3849
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 3848
[post_author] => 5
[post_date] => 2021-11-05 12:27:44
[post_date_gmt] => 2021-11-05 12:27:44
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:58:14
[post_modified_gmt] => 2022-04-18 08:58:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3848
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 3847
[post_author] => 5
[post_date] => 2021-11-05 12:25:40
[post_date_gmt] => 2021-11-05 12:25:40
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:07:16
[post_modified_gmt] => 2022-04-18 09:07:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3847
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 3846
[post_author] => 5
[post_date] => 2021-11-05 12:14:17
[post_date_gmt] => 2021-11-05 12:14:17
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:08:02
[post_modified_gmt] => 2022-04-18 09:08:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3846
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 3845
[post_author] => 5
[post_date] => 2021-11-05 11:56:34
[post_date_gmt] => 2021-11-05 11:56:34
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:20:20
[post_modified_gmt] => 2022-04-18 09:20:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3845
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 3819
[post_author] => 6
[post_date] => 2021-09-15 12:17:55
[post_date_gmt] => 2021-09-15 12:17:55
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 11:45:22
[post_modified_gmt] => 2021-12-15 11:45:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3819
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 3812
[post_author] => 5
[post_date] => 2021-09-10 12:44:57
[post_date_gmt] => 2021-09-10 12:44:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:13:50
[post_modified_gmt] => 2022-04-20 09:13:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3812
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 3810
[post_author] => 5
[post_date] => 2021-09-10 12:21:33
[post_date_gmt] => 2021-09-10 12:21:33
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:11:54
[post_modified_gmt] => 2022-04-20 07:11:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3810
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:19:45
[post_modified_gmt] => 2022-04-20 09:19:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:24:05
[post_modified_gmt] => 2022-04-20 07:24:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 3807
[post_author] => 5
[post_date] => 2021-09-10 11:55:25
[post_date_gmt] => 2021-09-10 11:55:25
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:42:12
[post_modified_gmt] => 2022-04-20 07:42:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 3806
[post_author] => 5
[post_date] => 2021-09-10 11:47:18
[post_date_gmt] => 2021-09-10 11:47:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:16:48
[post_modified_gmt] => 2022-04-20 09:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 3805
[post_author] => 5
[post_date] => 2021-09-10 11:33:53
[post_date_gmt] => 2021-09-10 11:33:53
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:46:59
[post_modified_gmt] => 2022-04-20 07:46:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 3804
[post_author] => 5
[post_date] => 2021-09-10 11:20:59
[post_date_gmt] => 2021-09-10 11:20:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:50:11
[post_modified_gmt] => 2022-04-20 07:50:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 3803
[post_author] => 5
[post_date] => 2021-09-10 10:54:42
[post_date_gmt] => 2021-09-10 10:54:42
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:51:06
[post_modified_gmt] => 2022-04-20 07:51:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3803
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 3802
[post_author] => 5
[post_date] => 2021-09-10 10:45:57
[post_date_gmt] => 2021-09-10 10:45:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:54:14
[post_modified_gmt] => 2022-04-20 07:54:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:05:17
[post_modified_gmt] => 2022-04-20 08:05:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 3800
[post_author] => 5
[post_date] => 2021-09-10 10:25:59
[post_date_gmt] => 2021-09-10 10:25:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:35:52
[post_modified_gmt] => 2022-04-20 08:35:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[152] => WP_Post Object
(
[ID] => 3799
[post_author] => 5
[post_date] => 2021-09-10 10:07:18
[post_date_gmt] => 2021-09-10 10:07:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:44:40
[post_modified_gmt] => 2022-04-20 08:44:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3799
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[153] => WP_Post Object
(
[ID] => 3798
[post_author] => 5
[post_date] => 2021-09-10 10:02:07
[post_date_gmt] => 2021-09-10 10:02:07
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:46:03
[post_modified_gmt] => 2022-04-20 08:46:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[154] => WP_Post Object
(
[ID] => 3797
[post_author] => 5
[post_date] => 2021-09-10 09:54:44
[post_date_gmt] => 2021-09-10 09:54:44
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:53:13
[post_modified_gmt] => 2022-04-20 08:53:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[155] => WP_Post Object
(
[ID] => 3796
[post_author] => 5
[post_date] => 2021-09-10 09:03:43
[post_date_gmt] => 2021-09-10 09:03:43
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:07:03
[post_modified_gmt] => 2022-04-20 09:07:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[156] => WP_Post Object
(
[ID] => 3792
[post_author] => 5
[post_date] => 2021-09-09 14:23:13
[post_date_gmt] => 2021-09-09 14:23:13
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 12:44:33
[post_modified_gmt] => 2022-03-09 12:44:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3792
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[157] => WP_Post Object
(
[ID] => 3791
[post_author] => 5
[post_date] => 2021-09-09 14:18:44
[post_date_gmt] => 2021-09-09 14:18:44
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:00:35
[post_modified_gmt] => 2021-11-04 09:00:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3791
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[158] => WP_Post Object
(
[ID] => 3789
[post_author] => 5
[post_date] => 2021-09-09 14:07:30
[post_date_gmt] => 2021-09-09 14:07:30
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:42:42
[post_modified_gmt] => 2022-01-27 11:42:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3789
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[159] => WP_Post Object
(
[ID] => 3788
[post_author] => 5
[post_date] => 2021-09-09 14:00:40
[post_date_gmt] => 2021-09-09 14:00:40
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:02:12
[post_modified_gmt] => 2021-11-04 09:02:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3788
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[160] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:55:09
[post_modified_gmt] => 2022-03-21 13:55:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[161] => WP_Post Object
(
[ID] => 3785
[post_author] => 5
[post_date] => 2021-09-09 13:10:11
[post_date_gmt] => 2021-09-09 13:10:11
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:04:36
[post_modified_gmt] => 2021-11-04 09:04:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3785
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[162] => WP_Post Object
(
[ID] => 3784
[post_author] => 5
[post_date] => 2021-09-09 13:03:52
[post_date_gmt] => 2021-09-09 13:03:52
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:12
[post_modified_gmt] => 2021-11-04 09:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3784
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[163] => WP_Post Object
(
[ID] => 3783
[post_author] => 5
[post_date] => 2021-09-09 12:41:47
[post_date_gmt] => 2021-09-09 12:41:47
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:50
[post_modified_gmt] => 2021-11-04 09:05:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3783
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[164] => WP_Post Object
(
[ID] => 3782
[post_author] => 5
[post_date] => 2021-09-09 12:36:36
[post_date_gmt] => 2021-09-09 12:36:36
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:50:50
[post_modified_gmt] => 2022-03-28 10:50:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[165] => WP_Post Object
(
[ID] => 3781
[post_author] => 5
[post_date] => 2021-09-09 12:29:54
[post_date_gmt] => 2021-09-09 12:29:54
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:18:43
[post_modified_gmt] => 2021-11-23 14:18:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3781
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[166] => WP_Post Object
(
[ID] => 3778
[post_author] => 5
[post_date] => 2021-09-09 11:52:53
[post_date_gmt] => 2021-09-09 11:52:53
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:35:12
[post_modified_gmt] => 2021-12-06 12:35:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3778
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[167] => WP_Post Object
(
[ID] => 3769
[post_author] => 5
[post_date] => 2021-09-02 14:55:06
[post_date_gmt] => 2021-09-02 14:55:06
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-novavax-covid-19-vaccine-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-02 15:00:21
[post_modified_gmt] => 2021-12-02 15:00:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3769
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[168] => WP_Post Object
(
[ID] => 3768
[post_author] => 5
[post_date] => 2021-09-02 14:27:00
[post_date_gmt] => 2021-09-02 14:27:00
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:19:56
[post_modified_gmt] => 2021-12-03 14:19:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3768
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[169] => WP_Post Object
(
[ID] => 3765
[post_author] => 5
[post_date] => 2021-09-01 14:09:03
[post_date_gmt] => 2021-09-01 14:09:03
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:49:00
[post_modified_gmt] => 2022-03-28 10:49:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[170] => WP_Post Object
(
[ID] => 3764
[post_author] => 5
[post_date] => 2021-09-01 12:17:32
[post_date_gmt] => 2021-09-01 12:17:32
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:15:32
[post_modified_gmt] => 2021-11-23 14:15:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3764
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[171] => WP_Post Object
(
[ID] => 3758
[post_author] => 5
[post_date] => 2021-08-26 12:04:03
[post_date_gmt] => 2021-08-26 12:04:03
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:43:14
[post_modified_gmt] => 2022-03-28 10:43:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[172] => WP_Post Object
(
[ID] => 3741
[post_author] => 5
[post_date] => 2021-08-24 09:13:39
[post_date_gmt] => 2021-08-24 09:13:39
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:32:22
[post_modified_gmt] => 2022-01-04 12:32:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[173] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:37:29
[post_modified_gmt] => 2022-01-18 12:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[174] => WP_Post Object
(
[ID] => 3495
[post_author] => 5
[post_date] => 2021-08-10 13:06:45
[post_date_gmt] => 2021-08-10 13:06:45
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dod-moderna-covid-19-vaccine-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:12:04
[post_modified_gmt] => 2021-11-29 14:12:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3495
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[175] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:24:35
[post_modified_gmt] => 2022-02-28 08:24:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[176] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:36
[post_modified_gmt] => 2022-04-18 09:22:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[177] => WP_Post Object
(
[ID] => 3434
[post_author] => 6
[post_date] => 2021-07-01 03:44:18
[post_date_gmt] => 2021-07-01 03:44:18
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:28:59
[post_modified_gmt] => 2022-04-18 09:28:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3434
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[178] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:32:11
[post_modified_gmt] => 2022-04-18 09:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[179] => WP_Post Object
(
[ID] => 3431
[post_author] => 6
[post_date] => 2021-07-01 03:38:49
[post_date_gmt] => 2021-07-01 03:38:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:41:10
[post_modified_gmt] => 2022-04-18 09:41:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3431
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[180] => WP_Post Object
(
[ID] => 3430
[post_author] => 6
[post_date] => 2021-07-01 03:27:51
[post_date_gmt] => 2021-07-01 03:27:51
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:45:31
[post_modified_gmt] => 2022-04-18 09:45:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3430
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[181] => WP_Post Object
(
[ID] => 3428
[post_author] => 6
[post_date] => 2021-07-01 03:24:00
[post_date_gmt] => 2021-07-01 03:24:00
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:47:22
[post_modified_gmt] => 2022-04-18 09:47:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3428
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[182] => WP_Post Object
(
[ID] => 3427
[post_author] => 6
[post_date] => 2021-07-01 03:22:23
[post_date_gmt] => 2021-07-01 03:22:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:49:38
[post_modified_gmt] => 2022-04-18 09:49:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[183] => WP_Post Object
(
[ID] => 3426
[post_author] => 6
[post_date] => 2021-07-01 03:06:23
[post_date_gmt] => 2021-07-01 03:06:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:28:05
[post_modified_gmt] => 2022-04-18 10:28:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[184] => WP_Post Object
(
[ID] => 3424
[post_author] => 6
[post_date] => 2021-07-01 03:03:57
[post_date_gmt] => 2021-07-01 03:03:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:47:10
[post_modified_gmt] => 2022-04-18 10:47:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[185] => WP_Post Object
(
[ID] => 3422
[post_author] => 6
[post_date] => 2021-07-01 02:58:21
[post_date_gmt] => 2021-07-01 02:58:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:48:25
[post_modified_gmt] => 2022-04-18 10:48:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[186] => WP_Post Object
(
[ID] => 3421
[post_author] => 6
[post_date] => 2021-07-01 02:56:30
[post_date_gmt] => 2021-07-01 02:56:30
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:51:44
[post_modified_gmt] => 2022-04-18 10:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3421
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[187] => WP_Post Object
(
[ID] => 3420
[post_author] => 6
[post_date] => 2021-07-01 02:52:05
[post_date_gmt] => 2021-07-01 02:52:05
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 11:01:10
[post_modified_gmt] => 2022-04-18 11:01:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3420
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[188] => WP_Post Object
(
[ID] => 3418
[post_author] => 5
[post_date] => 2021-06-30 19:06:19
[post_date_gmt] => 2021-06-30 19:06:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:03:49
[post_modified_gmt] => 2022-03-09 13:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3418
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[189] => WP_Post Object
(
[ID] => 3417
[post_author] => 5
[post_date] => 2021-06-30 19:04:34
[post_date_gmt] => 2021-06-30 19:04:34
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:39
[post_modified_gmt] => 2021-09-01 15:12:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3417
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[190] => WP_Post Object
(
[ID] => 3416
[post_author] => 5
[post_date] => 2021-06-30 19:02:19
[post_date_gmt] => 2021-06-30 19:02:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:57
[post_modified_gmt] => 2021-09-01 15:12:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3416
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[191] => WP_Post Object
(
[ID] => 3415
[post_author] => 5
[post_date] => 2021-06-30 19:00:20
[post_date_gmt] => 2021-06-30 19:00:20
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-30 12:40:36
[post_modified_gmt] => 2021-11-30 12:40:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3415
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[192] => WP_Post Object
(
[ID] => 3414
[post_author] => 5
[post_date] => 2021-06-30 18:54:43
[post_date_gmt] => 2021-06-30 18:54:43
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:08:59
[post_modified_gmt] => 2021-09-01 15:08:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3414
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[193] => WP_Post Object
(
[ID] => 3413
[post_author] => 5
[post_date] => 2021-06-30 18:52:08
[post_date_gmt] => 2021-06-30 18:52:08
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:10:41
[post_modified_gmt] => 2021-09-01 15:10:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3413
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[194] => WP_Post Object
(
[ID] => 3412
[post_author] => 5
[post_date] => 2021-06-30 18:48:13
[post_date_gmt] => 2021-06-30 18:48:13
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-11 13:32:40
[post_modified_gmt] => 2022-02-11 13:32:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3412
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[195] => WP_Post Object
(
[ID] => 3411
[post_author] => 5
[post_date] => 2021-06-30 18:39:53
[post_date_gmt] => 2021-06-30 18:39:53
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:11:28
[post_modified_gmt] => 2021-09-01 15:11:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3411
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[196] => WP_Post Object
(
[ID] => 3410
[post_author] => 5
[post_date] => 2021-06-30 18:37:02
[post_date_gmt] => 2021-06-30 18:37:02
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:09:38
[post_modified_gmt] => 2021-09-01 15:09:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3410
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[197] => WP_Post Object
(
[ID] => 3409
[post_author] => 5
[post_date] => 2021-06-30 18:34:04
[post_date_gmt] => 2021-06-30 18:34:04
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:58:15
[post_modified_gmt] => 2022-01-24 12:58:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3409
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[198] => WP_Post Object
(
[ID] => 3406
[post_author] => 5
[post_date] => 2021-06-30 18:25:58
[post_date_gmt] => 2021-06-30 18:25:58
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:11:44
[post_modified_gmt] => 2021-09-01 15:11:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3406
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[199] => WP_Post Object
(
[ID] => 3372
[post_author] => 5
[post_date] => 2021-06-30 15:06:19
[post_date_gmt] => 2021-06-30 15:06:19
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:05:39
[post_modified_gmt] => 2022-03-09 13:05:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3372
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[200] => WP_Post Object
(
[ID] => 3370
[post_author] => 5
[post_date] => 2021-06-30 15:01:06
[post_date_gmt] => 2021-06-30 15:01:06
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 11:51:17
[post_modified_gmt] => 2022-01-27 11:51:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3370
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[201] => WP_Post Object
(
[ID] => 3368
[post_author] => 5
[post_date] => 2021-06-30 14:58:39
[post_date_gmt] => 2021-06-30 14:58:39
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:10:31
[post_modified_gmt] => 2021-08-24 08:10:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3368
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[202] => WP_Post Object
(
[ID] => 3366
[post_author] => 5
[post_date] => 2021-06-30 14:53:53
[post_date_gmt] => 2021-06-30 14:53:53
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:53:53
[post_modified_gmt] => 2021-06-30 14:53:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3366
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[203] => WP_Post Object
(
[ID] => 3364
[post_author] => 5
[post_date] => 2021-06-30 14:47:34
[post_date_gmt] => 2021-06-30 14:47:34
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-02 12:46:22
[post_modified_gmt] => 2021-09-02 12:46:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3364
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[204] => WP_Post Object
(
[ID] => 3361
[post_author] => 5
[post_date] => 2021-06-30 14:30:51
[post_date_gmt] => 2021-06-30 14:30:51
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:22:31
[post_modified_gmt] => 2021-12-03 14:22:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3361
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[205] => WP_Post Object
(
[ID] => 3360
[post_author] => 5
[post_date] => 2021-06-30 14:28:40
[post_date_gmt] => 2021-06-30 14:28:40
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-07 11:53:01
[post_modified_gmt] => 2021-12-07 11:53:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3360
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[206] => WP_Post Object
(
[ID] => 3356
[post_author] => 5
[post_date] => 2021-06-30 13:53:23
[post_date_gmt] => 2021-06-30 13:53:23
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:44:11
[post_modified_gmt] => 2022-03-28 10:44:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[207] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[208] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-30 12:46:37
[post_modified_gmt] => 2022-03-30 12:46:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[209] => WP_Post Object
(
[ID] => 3304
[post_author] => 6
[post_date] => 2021-06-30 09:30:56
[post_date_gmt] => 2021-06-30 09:30:56
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:21
[post_modified_gmt] => 2021-08-23 10:01:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[210] => WP_Post Object
(
[ID] => 3221
[post_author] => 6
[post_date] => 2021-06-28 12:23:49
[post_date_gmt] => 2021-06-28 12:23:49
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:24
[post_modified_gmt] => 2021-08-23 09:51:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[211] => WP_Post Object
(
[ID] => 3220
[post_author] => 6
[post_date] => 2021-06-28 12:22:09
[post_date_gmt] => 2021-06-28 12:22:09
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:08:44
[post_modified_gmt] => 2022-03-09 13:08:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[212] => WP_Post Object
(
[ID] => 3219
[post_author] => 6
[post_date] => 2021-06-28 12:19:29
[post_date_gmt] => 2021-06-28 12:19:29
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:33
[post_modified_gmt] => 2021-08-23 09:51:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[213] => WP_Post Object
(
[ID] => 3218
[post_author] => 6
[post_date] => 2021-06-28 12:16:20
[post_date_gmt] => 2021-06-28 12:16:20
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:37
[post_modified_gmt] => 2021-08-23 09:51:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[214] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:41
[post_modified_gmt] => 2021-08-23 09:51:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[215] => WP_Post Object
(
[ID] => 3216
[post_author] => 6
[post_date] => 2021-06-28 12:11:22
[post_date_gmt] => 2021-06-28 12:11:22
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:45
[post_modified_gmt] => 2021-08-23 09:51:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[216] => WP_Post Object
(
[ID] => 3215
[post_author] => 6
[post_date] => 2021-06-28 12:07:55
[post_date_gmt] => 2021-06-28 12:07:55
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:48
[post_modified_gmt] => 2021-08-23 09:51:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[217] => WP_Post Object
(
[ID] => 3127
[post_author] => 6
[post_date] => 2021-06-03 15:08:41
[post_date_gmt] => 2021-06-03 15:08:41
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:45
[post_modified_gmt] => 2021-08-23 09:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[218] => WP_Post Object
(
[ID] => 3126
[post_author] => 6
[post_date] => 2021-06-03 15:05:40
[post_date_gmt] => 2021-06-03 15:05:40
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:49
[post_modified_gmt] => 2021-08-23 09:52:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[219] => WP_Post Object
(
[ID] => 3125
[post_author] => 6
[post_date] => 2021-06-03 15:03:17
[post_date_gmt] => 2021-06-03 15:03:17
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:13:17
[post_modified_gmt] => 2022-03-09 13:13:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[220] => WP_Post Object
(
[ID] => 3124
[post_author] => 6
[post_date] => 2021-06-03 15:01:23
[post_date_gmt] => 2021-06-03 15:01:23
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:56
[post_modified_gmt] => 2021-08-23 09:52:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[221] => WP_Post Object
(
[ID] => 3123
[post_author] => 6
[post_date] => 2021-06-03 14:51:22
[post_date_gmt] => 2021-06-03 14:51:22
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 13:12:13
[post_modified_gmt] => 2021-11-23 13:12:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[222] => WP_Post Object
(
[ID] => 3122
[post_author] => 6
[post_date] => 2021-06-03 14:45:44
[post_date_gmt] => 2021-06-03 14:45:44
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:08:08
[post_modified_gmt] => 2021-11-23 15:08:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[223] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:08
[post_modified_gmt] => 2021-08-23 09:53:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[224] => WP_Post Object
(
[ID] => 3120
[post_author] => 6
[post_date] => 2021-06-03 14:24:03
[post_date_gmt] => 2021-06-03 14:24:03
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:12
[post_modified_gmt] => 2021-08-23 09:53:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[225] => WP_Post Object
(
[ID] => 3119
[post_author] => 6
[post_date] => 2021-06-03 14:21:50
[post_date_gmt] => 2021-06-03 14:21:50
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:15
[post_modified_gmt] => 2021-08-23 09:53:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[226] => WP_Post Object
(
[ID] => 2956
[post_author] => 6
[post_date] => 2021-05-28 18:56:15
[post_date_gmt] => 2021-05-28 18:56:15
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:06
[post_modified_gmt] => 2021-08-23 10:02:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2956
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[227] => WP_Post Object
(
[ID] => 2961
[post_author] => 6
[post_date] => 2021-05-28 18:55:47
[post_date_gmt] => 2021-05-28 18:55:47
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:41:04
[post_modified_gmt] => 2021-11-23 12:41:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2961
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[228] => WP_Post Object
(
[ID] => 2965
[post_author] => 6
[post_date] => 2021-05-28 18:55:12
[post_date_gmt] => 2021-05-28 18:55:12
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:15
[post_modified_gmt] => 2021-08-23 10:02:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2965
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[229] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:17
[post_modified_gmt] => 2021-08-23 10:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[230] => WP_Post Object
(
[ID] => 2960
[post_author] => 6
[post_date] => 2021-05-28 18:53:36
[post_date_gmt] => 2021-05-28 18:53:36
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:20
[post_modified_gmt] => 2021-08-23 10:02:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2960
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[231] => WP_Post Object
(
[ID] => 2964
[post_author] => 6
[post_date] => 2021-05-28 18:53:11
[post_date_gmt] => 2021-05-28 18:53:11
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:24
[post_modified_gmt] => 2021-08-23 10:02:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2964
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[232] => WP_Post Object
(
[ID] => 2958
[post_author] => 6
[post_date] => 2021-05-28 18:52:54
[post_date_gmt] => 2021-05-28 18:52:54
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:13:48
[post_modified_gmt] => 2021-12-03 10:13:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2958
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[233] => WP_Post Object
(
[ID] => 2949
[post_author] => 6
[post_date] => 2021-05-28 18:52:06
[post_date_gmt] => 2021-05-28 18:52:06
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:37:55
[post_modified_gmt] => 2021-11-23 12:37:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2949
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[234] => WP_Post Object
(
[ID] => 2957
[post_author] => 6
[post_date] => 2021-05-28 18:51:39
[post_date_gmt] => 2021-05-28 18:51:39
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:00:44
[post_modified_gmt] => 2022-01-27 12:00:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2957
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[235] => WP_Post Object
(
[ID] => 2962
[post_author] => 6
[post_date] => 2021-05-28 18:50:18
[post_date_gmt] => 2021-05-28 18:50:18
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:38:17
[post_modified_gmt] => 2021-11-23 12:38:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2962
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[236] => WP_Post Object
(
[ID] => 2945
[post_author] => 6
[post_date] => 2021-05-28 14:03:27
[post_date_gmt] => 2021-05-28 14:03:27
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:13:02
[post_modified_gmt] => 2021-12-03 10:13:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2945
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[237] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:35:40
[post_modified_gmt] => 2022-02-28 08:35:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[238] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 08:59:23
[post_modified_gmt] => 2022-02-28 08:59:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[239] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 09:05:23
[post_modified_gmt] => 2022-02-28 09:05:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[240] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 09:23:17
[post_modified_gmt] => 2022-02-28 09:23:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[241] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-01 10:11:21
[post_modified_gmt] => 2022-04-01 10:11:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[242] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:45:33
[post_modified_gmt] => 2022-03-28 10:45:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[243] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 10:58:28
[post_modified_gmt] => 2022-02-28 10:58:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[244] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:01:15
[post_modified_gmt] => 2022-02-28 14:01:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[245] => WP_Post Object
(
[ID] => 2873
[post_author] => 6
[post_date] => 2021-05-11 15:17:08
[post_date_gmt] => 2021-05-11 15:17:08
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:50:47
[post_modified_gmt] => 2021-11-22 15:50:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[246] => WP_Post Object
(
[ID] => 2872
[post_author] => 6
[post_date] => 2021-05-11 15:14:24
[post_date_gmt] => 2021-05-11 15:14:24
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-06 12:00:31
[post_modified_gmt] => 2021-12-06 12:00:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2872
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[247] => WP_Post Object
(
[ID] => 2870
[post_author] => 6
[post_date] => 2021-05-11 15:07:59
[post_date_gmt] => 2021-05-11 15:07:59
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-15 09:15:21
[post_modified_gmt] => 2021-06-15 09:15:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[248] => WP_Post Object
(
[ID] => 2869
[post_author] => 6
[post_date] => 2021-05-11 14:53:04
[post_date_gmt] => 2021-05-11 14:53:04
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:15:00
[post_modified_gmt] => 2021-05-14 09:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[249] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 12:12:41
[post_modified_gmt] => 2022-05-24 12:12:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[250] => WP_Post Object
(
[ID] => 2824
[post_author] => 5
[post_date] => 2021-04-16 16:39:49
[post_date_gmt] => 2021-04-16 16:39:49
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:31:21
[post_modified_gmt] => 2022-01-27 12:31:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2824
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[251] => WP_Post Object
(
[ID] => 2823
[post_author] => 5
[post_date] => 2021-04-16 16:17:11
[post_date_gmt] => 2021-04-16 16:17:11
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:36:43
[post_modified_gmt] => 2022-01-18 12:36:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2823
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[252] => WP_Post Object
(
[ID] => 2822
[post_author] => 5
[post_date] => 2021-04-16 16:09:31
[post_date_gmt] => 2021-04-16 16:09:31
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:48:13
[post_modified_gmt] => 2022-01-18 12:48:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2822
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[253] => WP_Post Object
(
[ID] => 2820
[post_author] => 5
[post_date] => 2021-04-16 12:44:14
[post_date_gmt] => 2021-04-16 12:44:14
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:50:08
[post_modified_gmt] => 2022-01-18 12:50:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2820
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[254] => WP_Post Object
(
[ID] => 2744
[post_author] => 5
[post_date] => 2021-03-30 15:12:35
[post_date_gmt] => 2021-03-30 15:12:35
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:48:08
[post_modified_gmt] => 2021-08-12 13:48:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[255] => WP_Post Object
(
[ID] => 2749
[post_author] => 5
[post_date] => 2021-03-30 15:10:16
[post_date_gmt] => 2021-03-30 15:10:16
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:54:16
[post_modified_gmt] => 2021-08-12 13:54:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[256] => WP_Post Object
(
[ID] => 2748
[post_author] => 5
[post_date] => 2021-03-30 15:05:46
[post_date_gmt] => 2021-03-30 15:05:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2748
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:52:39
[post_modified_gmt] => 2021-08-12 13:52:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[257] => WP_Post Object
(
[ID] => 2743
[post_author] => 5
[post_date] => 2021-03-24 15:11:40
[post_date_gmt] => 2021-03-24 15:11:40
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:33:45
[post_modified_gmt] => 2022-01-27 12:33:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[258] => WP_Post Object
(
[ID] => 2742
[post_author] => 5
[post_date] => 2021-03-24 13:37:07
[post_date_gmt] => 2021-03-24 13:37:07
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:28:13
[post_modified_gmt] => 2021-08-12 12:28:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2742
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[259] => WP_Post Object
(
[ID] => 2741
[post_author] => 5
[post_date] => 2021-03-24 13:32:55
[post_date_gmt] => 2021-03-24 13:32:55
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:06:52
[post_modified_gmt] => 2021-11-23 15:06:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[260] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:47:55
[post_modified_gmt] => 2022-03-28 10:47:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[261] => WP_Post Object
(
[ID] => 2737
[post_author] => 5
[post_date] => 2021-03-24 13:00:46
[post_date_gmt] => 2021-03-24 13:00:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:45:35
[post_modified_gmt] => 2021-08-12 12:45:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2737
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[262] => WP_Post Object
(
[ID] => 2736
[post_author] => 5
[post_date] => 2021-03-23 18:15:15
[post_date_gmt] => 2021-03-23 18:15:15
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 14:50:37
[post_modified_gmt] => 2021-12-03 14:50:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[263] => WP_Post Object
(
[ID] => 2734
[post_author] => 5
[post_date] => 2021-03-23 18:01:22
[post_date_gmt] => 2021-03-23 18:01:22
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 10:29:04
[post_modified_gmt] => 2021-09-03 10:29:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2734
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[264] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 18:43:53
[post_modified_gmt] => 2022-01-04 18:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[265] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 09:35:45
[post_modified_gmt] => 2022-01-05 09:35:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[266] => WP_Post Object
(
[ID] => 2541
[post_author] => 5
[post_date] => 2021-03-12 18:11:14
[post_date_gmt] => 2021-03-12 18:11:14
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:49:36
[post_modified_gmt] => 2022-01-05 10:49:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2541
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[267] => WP_Post Object
(
[ID] => 2542
[post_author] => 5
[post_date] => 2021-03-12 14:21:07
[post_date_gmt] => 2021-03-12 14:21:07
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:17:48
[post_modified_gmt] => 2022-01-05 10:17:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2542
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[268] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:10:55
[post_modified_gmt] => 2022-03-28 10:10:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[269] => WP_Post Object
(
[ID] => 2545
[post_author] => 5
[post_date] => 2021-03-12 14:14:38
[post_date_gmt] => 2021-03-12 14:14:38
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:14:28
[post_modified_gmt] => 2022-03-09 13:14:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2545
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[270] => WP_Post Object
(
[ID] => 2547
[post_author] => 5
[post_date] => 2021-03-12 13:58:55
[post_date_gmt] => 2021-03-12 13:58:55
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:38:40
[post_modified_gmt] => 2022-01-27 12:38:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2547
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[271] => WP_Post Object
(
[ID] => 2549
[post_author] => 5
[post_date] => 2021-03-12 13:50:41
[post_date_gmt] => 2021-03-12 13:50:41
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 08:48:43
[post_modified_gmt] => 2022-01-05 08:48:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[272] => WP_Post Object
(
[ID] => 2553
[post_author] => 5
[post_date] => 2021-03-12 13:47:42
[post_date_gmt] => 2021-03-12 13:47:42
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:59:58
[post_modified_gmt] => 2022-01-05 10:59:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2553
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[273] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 12:14:51
[post_modified_gmt] => 2021-09-03 12:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[274] => WP_Post Object
(
[ID] => 2461
[post_author] => 5
[post_date] => 2021-02-25 15:23:35
[post_date_gmt] => 2021-02-25 15:23:35
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:19:55
[post_modified_gmt] => 2021-08-24 08:19:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[275] => WP_Post Object
(
[ID] => 2462
[post_author] => 5
[post_date] => 2021-02-25 15:23:19
[post_date_gmt] => 2021-02-25 15:23:19
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 13:28:17
[post_modified_gmt] => 2021-09-03 13:28:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[276] => WP_Post Object
(
[ID] => 2463
[post_author] => 5
[post_date] => 2021-02-25 15:22:52
[post_date_gmt] => 2021-02-25 15:22:52
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 13:35:23
[post_modified_gmt] => 2021-09-03 13:35:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2463
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[277] => WP_Post Object
(
[ID] => 2464
[post_author] => 5
[post_date] => 2021-02-25 15:21:51
[post_date_gmt] => 2021-02-25 15:21:51
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:13:03
[post_modified_gmt] => 2021-11-23 15:13:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2464
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[278] => WP_Post Object
(
[ID] => 2465
[post_author] => 5
[post_date] => 2021-02-25 15:21:32
[post_date_gmt] => 2021-02-25 15:21:32
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:40:25
[post_modified_gmt] => 2022-01-27 12:40:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2465
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[279] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:50:01
[post_modified_gmt] => 2022-03-28 10:50:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[280] => WP_Post Object
(
[ID] => 2467
[post_author] => 5
[post_date] => 2021-02-25 15:20:15
[post_date_gmt] => 2021-02-25 15:20:15
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:15:33
[post_modified_gmt] => 2022-03-09 13:15:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[281] => WP_Post Object
(
[ID] => 2470
[post_author] => 5
[post_date] => 2021-01-25 13:24:13
[post_date_gmt] => 2021-01-25 13:24:13
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 13:54:22
[post_modified_gmt] => 2022-03-28 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2470
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[282] => WP_Post Object
(
[ID] => 2473
[post_author] => 5
[post_date] => 2021-01-25 13:21:58
[post_date_gmt] => 2021-01-25 13:21:58
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:14:59
[post_modified_gmt] => 2022-01-04 14:14:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2473
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[283] => WP_Post Object
(
[ID] => 2474
[post_author] => 5
[post_date] => 2021-01-25 13:19:34
[post_date_gmt] => 2021-01-25 13:19:34
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:54:44
[post_modified_gmt] => 2022-01-04 12:54:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2474
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[284] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 11:57:00
[post_modified_gmt] => 2022-01-04 11:57:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[285] => WP_Post Object
(
[ID] => 2476
[post_author] => 5
[post_date] => 2021-01-25 13:18:09
[post_date_gmt] => 2021-01-25 13:18:09
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:42:48
[post_modified_gmt] => 2022-01-04 12:42:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2476
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[286] => WP_Post Object
(
[ID] => 2477
[post_author] => 5
[post_date] => 2021-01-25 13:16:23
[post_date_gmt] => 2021-01-25 13:16:23
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:38:40
[post_modified_gmt] => 2022-03-08 13:38:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2477
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[287] => WP_Post Object
(
[ID] => 2479
[post_author] => 5
[post_date] => 2021-01-25 13:12:32
[post_date_gmt] => 2021-01-25 13:12:32
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-27 12:42:15
[post_modified_gmt] => 2022-01-27 12:42:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[288] => WP_Post Object
(
[ID] => 2481
[post_author] => 5
[post_date] => 2021-01-25 13:11:08
[post_date_gmt] => 2021-01-25 13:11:08
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 10:39:14
[post_modified_gmt] => 2022-01-19 10:39:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[289] => WP_Post Object
(
[ID] => 2482
[post_author] => 5
[post_date] => 2021-01-25 13:09:37
[post_date_gmt] => 2021-01-25 13:09:37
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:23:50
[post_modified_gmt] => 2022-01-04 14:23:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[290] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 13:51:57
[post_modified_gmt] => 2022-01-04 13:51:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[291] => WP_Post Object
(
[ID] => 2454
[post_author] => 5
[post_date] => 2021-01-19 11:44:16
[post_date_gmt] => 2021-01-19 11:44:16
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:28:26
[post_modified_gmt] => 2021-11-23 14:28:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2454
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[292] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:12:55
[post_modified_gmt] => 2022-03-28 10:12:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>